CDC Proportional Reporting Ratio

VAERS Standard Operating Procedures for COVID-19

CDC tried to hide the results of its VAERS signal detection data from ICAN and the rest of the country. When you understand this data, you will also understand why. According to CDC's VAERS Standard Operating Procedures, a “safety signal” is defined as a condition that has a PRR>=2.00, N>=3, and Chi-Square>=4.00. And as you will see below, numerous concerning conditions blow these numbers away! To download all PRR data (excel files), click here.

  • PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
  • For Current Week and Past Week Comparison
  • Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
  • Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
  • AGES 5 YEARS-11 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
  • Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
  • N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
  • MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
  • AGES 5 YEARS-11 YEARS excludes missing ages
MedDRA Codes ALL Reports (5 Yrs-11 Yrs) 12/14/2020-03/18/2022 COVID19 mRNA N=9256 01/01/2009-03/18/2022 NON-COVID19 N=49819 12/14-03/18 Chi-Square 12/14-03/18 PRR 12/14-03/18 LCL 12/14-03/18 UCL
PRODUCT PREPARATION ISSUE 1506 37 8043.27 219.08 158.23 303.33
COVID-19 133 4 682.64 178.96 66.21 483.74
INCORRECT DOSE ADMINISTERED 1501 251 6691.23 32.19 28.21 36.72
UNDERDOSE 397 81 1650.96 26.38 20.79 33.47
PRODUCT ADMINISTRATION ERROR 61 8 271.12 41.04 19.65 85.73
IMMUNISATION 71 13 296.64 29.40 16.28 53.08
ILLNESS 25 3 109.39 44.85 13.55 148.52
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 1217 439 4306.57 14.92 13.41 16.60
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 209 86 678.99 13.08 10.19 16.80
INCORRECT PRODUCT FORMULATION ADMINISTERED 141 60 448.93 12.65 9.36 17.10
APPENDICITIS 16 4 57.89 21.53 7.20 64.38
PRODUCT PREPARATION ERROR 122 75 316.63 8.76 6.57 11.66
MYOCARDITIS 14 4 47.97 18.84 6.20 57.22
INJURY ASSOCIATED WITH DEVICE 12 3 42.25 21.53 6.08 76.28
PRODUCT USE ISSUE 23 10 68.91 12.38 5.89 26.00
ANGINA PECTORIS 11 3 37.31 19.74 5.51 70.73
PHARYNGEAL SWELLING 12 4 38.27 16.15 5.21 50.05
WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 50 34 119.14 7.92 5.12 12.23
MENSTRUATION IRREGULAR 10 3 32.43 17.94 4.94 65.18
OROPHARYNGEAL DISCOMFORT 10 3 32.43 17.94 4.94 65.18
NEEDLE ISSUE 13 6 36.13 11.66 4.43 30.67
CHEST PAIN 164 188 253.91 4.70 3.81 5.78
SYRINGE ISSUE 37 34 68.72 5.86 3.68 9.33
PERIORBITAL SWELLING 13 8 30.58 8.75 3.63 21.10
NO ADVERSE EVENT 1996 2839 2612.62 3.78 3.59 3.99
CONJUNCTIVITIS 28 25 52.66 6.03 3.52 10.33
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR 38 38 65.31 5.38 3.44 8.43
VACCINATION FAILURE 16 12 33.40 7.18 3.40 15.16
OVERDOSE 20 17 38.43 6.33 3.32 12.08
APPENDICECTOMY 12 8 26.50 8.07 3.30 19.75
KAWASAKI'S DISEASE 7 3 18.42 12.56 3.25 48.56
PITYRIASIS ROSEA 8 4 19.92 10.76 3.24 35.74
CHEST DISCOMFORT 60 81 75.29 3.99 2.86 5.56
PAINFUL RESPIRATION 12 10 22.32 6.46 2.79 14.94
PRODUCT STORAGE ERROR 461 807 418.14 3.07 2.75 3.44
OFF LABEL USE 21 25 29.09 4.52 2.53 8.07
EXPIRED PRODUCT ADMINISTERED 271 510 215.48 2.86 2.47 3.31
SLEEP DISORDER 31 44 35.52 3.79 2.40 6.00
LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 39 63 37.69 3.33 2.24 4.96
FATIGUE 391 860 233.79 2.45 2.18 2.75
VENTRICULAR EXTRASYSTOLES 5 3 9.97 8.97 2.14 37.53
FEELING COLD 33 57 28.51 3.12 2.03 4.78
ADVERSE EVENT 12 15 14.82 4.31 2.02 9.20
SWELLING OF EYELID 13 17 15.35 4.12 2.00 8.47
PALPITATIONS 31 54 26.32 3.09 1.99 4.80
INCORRECT ROUTE OF PRODUCT ADMINISTRATION 18 27 18.38 3.59 1.98 6.51
SHOCK 7 7 10.03 5.38 1.89 15.34
CHILLS 145 344 71.91 2.27 1.87 2.75
SEIZURE 100 232 51.68 2.32 1.84 2.93
FEEDING DISORDER 9 11 10.90 4.40 1.83 10.62
HEAD DISCOMFORT 10 13 11.44 4.14 1.82 9.44
AXILLARY PAIN 27 51 19.81 2.85 1.79 4.54
MOUTH SWELLING 7 8 8.69 4.71 1.71 12.98
LYMPHADENOPATHY 70 169 32.67 2.23 1.69 2.94
CONDITION AGGRAVATED 89 226 37.01 2.12 1.66 2.71
AGEUSIA 4 3 6.24 7.18 1.61 32.06
CARDIAC DISORDER 4 3 6.24 7.18 1.61 32.06
SYNOVITIS 12 20 9.96 3.23 1.58 6.60
ABDOMINAL PAIN LOWER 7 9 7.54 4.19 1.56 11.24
MUSCULOSKELETAL CHEST PAIN 7 9 7.54 4.19 1.56 11.24
INJECTION SITE EXTRAVASATION 6 7 6.98 4.61 1.55 13.72
HAEMATURIA 10 17 7.79 3.17 1.45 6.91
GENERALISED TONIC-CLONIC SEIZURE 21 48 10.31 2.35 1.41 3.93
TINNITUS 20 45 10.12 2.39 1.41 4.05
GRIMACING 6 8 5.91 4.04 1.40 11.63
WOUND 6 8 5.91 4.04 1.40 11.63
INJECTION SITE PARAESTHESIA 5 6 5.30 4.49 1.37 14.69
NEPHROTIC SYNDROME 5 6 5.30 4.49 1.37 14.69
LIMB DISCOMFORT 18 41 8.75 2.36 1.36 4.11
GIANOTTI-CROSTI SYNDROME 4 4 4.78 5.38 1.35 21.52
NERVOUSNESS 22 54 9.17 2.19 1.34 3.60
VOMITING PROJECTILE 7 11 5.69 3.43 1.33 8.83
ADVERSE REACTION 10 19 6.41 2.83 1.32 6.09
HYPOPNOEA 7 12 4.95 3.14 1.24 7.97
LIP BLISTER 5 7 4.33 3.84 1.22 12.11
HEART RATE DECREASED 15 37 5.88 2.18 1.20 3.97
HAEMORRHAGE 12 28 5.18 2.31 1.17 4.53
DERMATITIS 6 10 4.24 3.23 1.17 8.88
PANIC ATTACK 9 19 4.57 2.55 1.15 5.63
DRY EYE 4 3 6.24 7.18 1.61 32.06
MOTION SICKNESS 4 3 6.24 7.18 1.61 32.06
PRODUCT ADMINISTERED AT INAPPROPRIATE SITE 13 22 10.65 3.18 1.60 6.31
ABDOMINAL DISCOMFORT 44 112 17.67 2.11 1.49 2.99
ALOPECIA AREATA 6 8 5.91 4.04 1.40 11.63
CHAPPED LIPS 6 8 5.91 4.04 1.40 11.63
ORAL MUCOSAL ERUPTION 5 6 5.30 4.49 1.37 14.69
SENSATION OF FOREIGN BODY 9 18 5.11 2.69 1.21 5.99
INTERCHANGE OF VACCINE PRODUCTS 9 19 4.57 2.55 1.15 5.63
DRY SKIN 13 33 4.61 2.12 1.12 4.03
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN 33 1 164.45 177.62 24.30 1298.48
BELL'S PALSY 15 1 68.05 80.74 10.67 611.12
DRUG INEFFECTIVE 14 2 57.18 37.68 8.56 165.75
LEFT VENTRICULAR DYSFUNCTION 9 1 36.39 48.44 6.14 382.30
MENSTRUAL DISORDER 8 2 26.65 21.53 4.57 101.37
COSTOCHONDRITIS 7 2 21.79 18.84 3.91 90.67
TASTE DISORDER 7 2 21.79 18.84 3.91 90.67
PERICARDIAL EFFUSION 6 1 20.96 32.29 3.89 268.21
PERICARDITIS 6 1 20.96 32.29 3.89 268.21
POOR QUALITY PRODUCT ADMINISTERED 6 1 20.96 32.29 3.89 268.21
APHONIA 5 2 12.52 13.46 2.61 69.34
APHTHOUS ULCER 5 2 12.52 13.46 2.61 69.34
SINUS TACHYCARDIA 5 2 12.52 13.46 2.61 69.34
DEVICE CONNECTION ISSUE 4 2 8.27 10.76 1.97 58.76
HEPATOMEGALY 4 2 8.27 10.76 1.97 58.76
OCULAR DISCOMFORT 4 2 8.27 10.76 1.97 58.76
PAROSMIA 4 2 8.27 10.76 1.97 58.76
BLOOD PRESSURE DIASTOLIC DECREASED 3 1 6.64 16.15 1.68 155.21
STRAWBERRY TONGUE 3 1 6.64 16.15 1.68 155.21
TRICUSPID VALVE INCOMPETENCE 3 1 6.64 16.15 1.68 155.21
HORDEOLUM 3 2 4.46 8.07 1.35 48.31
PLEURAL EFFUSION 3 2 4.46 8.07 1.35 48.31
PRODUCT ADMINISTRATION INTERRUPTED 3 2 4.46 8.07 1.35 48.31
RESPIRATORY SYNCYTIAL VIRUS INFECTION 3 2 4.46 8.07 1.35 48.31
TENSION HEADACHE 3 2 4.46 8.07 1.35 48.31
VACCINATION SITE URTICARIA 3 2 4.46 8.07 1.35 48.31
BEHAVIOUR DISORDER 4 1 11.17 21.53 2.41 192.60
  • PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
  • For Current Week and Past Week Comparison
  • Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
  • Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
  • AGES 12 YEARS-17 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
  • Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
  • N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
  • MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
  • AGES 12 YEARS-17 YEARS excludes missing ages
MedDRA Codes ALL Reports (12 Yrs-17 Yrs) 12/14/2020-03/18/2022 COVID19 mRNA N=21791 01/01/2009-03/18/2022 NON-COVID19 N=48026 12/14-03/18 Chi-Square 12/14-03/18 PRR 12/14-03/18 LCL 12/14-03/18 UCL
COVID-19 458 3 1000.32 336.47 108.13 1046.99
MYOCARDITIS 709 12 1525.71 130.22 73.62 230.33
UNDERDOSE 959 58 1910.04 36.44 27.97 47.48
HEAVY MENSTRUAL BLEEDING 123 5 248.42 54.22 22.18 132.56
PERICARDITIS 210 12 413.77 38.57 21.56 68.99
PRODUCT PREPARATION ISSUE 516 57 928.90 19.95 15.18 26.22
ILLNESS 72 5 136.44 31.74 12.82 78.55
ANTICOAGULANT THERAPY 53 4 98.52 29.20 10.57 80.67
PERICARDIAL EFFUSION 67 7 118.70 21.09 9.69 45.94
PRODUCT ADMINISTRATION ERROR 47 4 85.48 25.90 9.33 71.87
AGEUSIA 66 8 113.29 18.18 8.73 37.87
IMMUNISATION 96 14 158.67 15.11 8.63 26.47
ANGINA PECTORIS 48 5 84.29 21.16 8.42 53.14
PLEURITIC PAIN 48 5 84.29 21.16 8.42 53.14
CHEST PAIN 1760 463 2457.68 8.38 7.57 9.27
PAINFUL RESPIRATION 131 26 197.49 11.10 7.29 16.91
PHARYNGEAL SWELLING 74 14 112.30 11.65 6.58 20.62
FEAR OF INJECTION 35 5 56.47 15.43 6.05 39.37
PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 1425 532 1621.22 5.90 5.35 6.51
RESPIRATORY RATE INCREASED 174 53 216.91 7.24 5.32 9.84
VENTRICULAR EXTRASYSTOLES 33 6 49.38 12.12 5.08 28.92
PULMONARY EMBOLISM 29 5 43.86 12.78 4.95 33.02
TRICUSPID VALVE INCOMPETENCE 25 4 38.35 13.77 4.79 39.57
PRODUCT STORAGE ERROR 1977 853 2050.04 5.11 4.72 5.53
RESPIRATORY RATE DECREASED 42 10 57.24 9.26 4.65 18.44
CHEST DISCOMFORT 609 251 634.19 5.35 4.62 6.19
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 463 192 478.05 5.31 4.50 6.28
BLOOD PRESSURE INCREASED 170 63 187.85 5.95 4.46 7.94
SINUS ARRHYTHMIA 29 6 41.13 10.65 4.42 25.65
APPENDICITIS 58 17 72.25 7.52 4.38 12.91
THROMBOSIS 32 8 42.13 8.82 4.06 19.13
PERIORBITAL SWELLING 21 4 30.05 11.57 3.97 33.70
ACUTE KIDNEY INJURY 31 8 40.14 8.54 3.93 18.58
OROPHARYNGEAL DISCOMFORT 38 11 46.91 7.61 3.89 14.89
INTENSIVE CARE 341 161 315.77 4.67 3.87 5.63
HEART RATE INCREASED 434 212 391.27 4.51 3.83 5.31
VAGINAL ULCERATION 25 6 33.03 9.18 3.77 22.38
INCORRECT DOSE ADMINISTERED 678 351 583.33 4.26 3.75 4.84
SINUS TACHYCARDIA 61 22 67.24 6.11 3.75 9.95
FLUSHING 389 194 343.66 4.42 3.72 5.25
MENSTRUAL DISORDER 74 30 75.54 5.44 3.56 8.31
APHTHOUS ULCER 19 4 25.96 10.47 3.56 30.77
CARDIAC DISORDER 25 7 30.67 7.87 3.41 18.20
CARDIAC FLUTTER 25 7 30.67 7.87 3.41 18.20
PRODUCT TEMPERATURE EXCURSION ISSUE 27 8 32.30 7.44 3.38 16.37
IMMUNE THROMBOCYTOPENIA 20 5 25.50 8.82 3.31 23.49
TACHYPNOEA 66 29 63.09 5.02 3.24 7.76
PALPITATIONS 347 200 265.15 3.82 3.22 4.55
ELECTROCARDIOGRAM T WAVE INVERSION 15 3 20.42 11.02 3.19 38.06
HEART SOUNDS ABNORMAL 15 3 20.42 11.02 3.19 38.06
OVERDOSE 37 15 36.83 5.44 2.98 9.90
LYMPHOPENIA 14 3 18.40 10.29 2.96 35.79
LYMPHADENOPATHY 444 296 287.36 3.31 2.86 3.83
AXILLARY PAIN 94 52 73.44 3.98 2.84 5.59
DYSMENORRHOEA 63 32 52.98 4.34 2.84 6.64
SLEEP DISORDER 150 93 104.35 3.55 2.75 4.60
PAROSMIA 24 9 24.60 5.88 2.73 12.64
TACHYCARDIA 321 224 194.83 3.16 2.66 3.74
NEEDLE ISSUE 18 6 19.45 6.61 2.62 16.65
RESPIRATORY SYMPTOM 18 6 19.45 6.61 2.62 16.65
HYPERHIDROSIS 1102 859 585.42 2.83 2.59 3.09
MOUTH SWELLING 21 8 21.06 5.79 2.56 13.06
DYSPNOEA EXERTIONAL 45 24 35.63 4.13 2.52 6.78
APPENDICECTOMY 46 25 35.77 4.06 2.49 6.60
SENSITIVE SKIN 12 3 14.44 8.82 2.49 31.24
SINUS BRADYCARDIA 28 13 24.57 4.75 2.46 9.16
TRANSAMINASES INCREASED 17 6 17.60 6.24 2.46 15.84
DYSPNOEA 1244 1030 603.16 2.66 2.45 2.89
PRODUCT PREPARATION ERROR 152 107 90.13 3.13 2.45 4.01
UNRESPONSIVE TO STIMULI 633 511 314.03 2.73 2.43 3.06
EXPIRED PRODUCT ADMINISTERED 559 453 274.95 2.72 2.41 3.08
DECREASED ACTIVITY 50 29 36.43 3.80 2.41 6.00
HYPOTENSION 343 269 176.19 2.81 2.40 3.29
SWELLING OF EYELID 33 17 26.61 4.28 2.38 7.68
STEROID THERAPY 18 7 17.53 5.67 2.37 13.57
ACUTE RESPIRATORY FAILURE 21 9 19.26 5.14 2.36 11.23
SYRINGE ISSUE 52 32 35.48 3.58 2.31 5.56
BLOOD GLUCOSE INCREASED 16 6 15.79 5.88 2.30 15.02
OLIGOMENORRHOEA 16 6 15.79 5.88 2.30 15.02
HYPERTENSION 88 61 52.65 3.18 2.29 4.41
CONDITION AGGRAVATED 379 316 176.73 2.64 2.28 3.07
VACCINATION SITE PAIN 108 78 61.39 3.05 2.28 4.08
NERVOUSNESS 137 104 72.83 2.90 2.25 3.74
BLOOD GLUCOSE DECREASED 14 5 14.05 6.17 2.22 17.13
MUSCULOSKELETAL CHEST PAIN 60 41 36.15 3.23 2.17 4.80
OXYGEN SATURATION DECREASED 55 37 33.71 3.28 2.16 4.97
VACCINATION SITE RASH 18 8 15.78 4.96 2.16 11.40
LYMPH NODE PAIN 76 55 42.68 3.05 2.15 4.31
PLEURAL EFFUSION 26 14 19.74 4.09 2.14 7.84
CARDIOMEGALY 15 6 14.01 5.51 2.14 14.20
HEART RATE IRREGULAR 41 26 26.70 3.48 2.13 5.68
BREATH SOUNDS ABNORMAL 36 22 24.33 3.61 2.12 6.13
CHILLS 946 902 351.95 2.31 2.11 2.53
DEAFNESS 69 50 38.55 3.04 2.11 4.38
SEIZURE 500 464 193.28 2.37 2.10 2.69
CARDIAC ARREST 24 13 17.99 4.07 2.07 7.99
POLYMENORRHOEA 16 7 14.03 5.04 2.07 12.24
IMMUNOGLOBULIN THERAPY 185 160 80.07 2.55 2.06 3.15
EPISTAXIS 133 112 59.90 2.62 2.04 3.36
IMMUNODEFICIENCY 13 5 12.26 5.73 2.04 16.07
MENSTRUATION IRREGULAR 88 70 43.08 2.77 2.03 3.79
RHINOVIRUS INFECTION 10 3 10.61 7.35 2.02 26.69
THROAT TIGHTNESS 208 189 82.44 2.43 1.99 2.95
HEART RATE DECREASED 118 100 52.43 2.60 1.99 3.39
GAIT INABILITY 52 38 28.40 3.02 1.99 4.58
BREAST PAIN 11 4 10.51 6.06 1.93 19.03
PANCREATITIS ACUTE 11 4 10.51 6.06 1.93 19.03
MENSTRUATION DELAYED 26 16 17.04 3.58 1.92 6.67
NASAL CONGESTION 168 156 63.63 2.37 1.91 2.95
LIP DISCOLOURATION 16 8 12.45 4.41 1.89 10.30
INCORRECT PRODUCT FORMULATION ADMINISTERED 97 85 40.43 2.52 1.88 3.36
EXTRA DOSE ADMINISTERED 335 339 107.52 2.18 1.87 2.53
FEEDING DISORDER 32 23 17.41 3.07 1.79 5.24
HEPATIC STEATOSIS 9 3 8.78 6.61 1.79 24.42
FACIAL PARALYSIS 56 48 23.81 2.57 1.75 3.78
HYPOXIA 30 22 15.78 3.01 1.73 5.21
CARDIAC FAILURE 10 4 8.76 5.51 1.73 17.57
ELECTROCARDIOGRAM QT PROLONGED 10 4 8.76 5.51 1.73 17.57
ORTHOPNOEA 10 4 8.76 5.51 1.73 17.57
BLINDNESS 106 105 34.80 2.22 1.70 2.91
INFLAMMATION 76 72 27.09 2.33 1.69 3.21
TRANSFUSION 20 13 11.95 3.39 1.69 6.81
ELECTROCARDIOGRAM AMBULATORY 11 5 8.83 4.85 1.68 13.95
EAR DISCOMFORT 32 25 15.37 2.82 1.67 4.76
TINNITUS 181 197 48.43 2.02 1.66 2.48
VACCINATION FAILURE 41 35 17.27 2.58 1.64 4.05
SUPRAVENTRICULAR TACHYCARDIA 15 9 9.54 3.67 1.61 8.39
DRY THROAT 17 11 10.02 3.41 1.60 7.27
SEPSIS 16 10 9.77 3.53 1.60 7.77
RHABDOMYOLYSIS 18 12 10.28 3.31 1.59 6.86
LIMB DISCOMFORT 85 88 25.11 2.13 1.58 2.87
LIP ERYTHEMA 8 3 7.00 5.88 1.56 22.15
TONGUE PRURITUS 8 3 7.00 5.88 1.56 22.15
HYPOPNOEA 29 24 12.58 2.66 1.55 4.57
CARDIOVERSION 9 4 7.07 4.96 1.53 16.10
PHARYNGEAL PARAESTHESIA 9 4 7.07 4.96 1.53 16.10
ABDOMINAL PAIN LOWER 40 38 13.73 2.32 1.49 3.62
TESTICULAR PAIN 15 10 8.36 3.31 1.49 7.36
ATELECTASIS 12 7 7.61 3.78 1.49 9.60
PLATELET COUNT DECREASED 12 7 7.61 3.78 1.49 9.60
BLOOD PRESSURE SYSTOLIC DECREASED 11 6 7.39 4.04 1.49 10.92
HYPOACUSIS 69 74 18.59 2.06 1.48 2.85
PANCYTOPENIA 14 9 8.09 3.43 1.48 7.92
PROTEINURIA 13 8 7.84 3.58 1.48 8.64
CONJUNCTIVITIS 23 19 9.79 2.67 1.45 4.90
DEEP VEIN THROMBOSIS 19 15 8.53 2.79 1.42 5.49
ARRHYTHMIA 22 19 8.61 2.55 1.38 4.71
INJECTION SITE BRUISING 35 36 10.00 2.14 1.35 3.41
BLOOD PRESSURE FLUCTUATION 12 8 6.44 3.31 1.35 8.09
BRAIN OEDEMA 10 6 5.91 3.67 1.34 10.11
CHAPPED LIPS 9 5 5.68 3.97 1.33 11.84
REFUSAL OF TREATMENT BY PATIENT 9 5 5.68 3.97 1.33 11.84
SUICIDE ATTEMPT 9 5 5.68 3.97 1.33 11.84
BREAST SWELLING 8 4 5.47 4.41 1.33 14.64
HEPATITIS 8 4 5.47 4.41 1.33 14.64
APRAXIA 7 3 5.32 5.14 1.33 19.88
CARDIAC MONITORING 7 3 5.32 5.14 1.33 19.88
CARDIOGENIC SHOCK 7 3 5.32 5.14 1.33 19.88
HAEMORRHAGE INTRACRANIAL 7 3 5.32 5.14 1.33 19.88
HYPOALBUMINAEMIA 7 3 5.32 5.14 1.33 19.88
SEPTIC SHOCK 7 3 5.32 5.14 1.33 19.88
PULMONARY OEDEMA 15 12 6.36 2.75 1.29 5.88
FEAR 32 34 8.39 2.07 1.28 3.36
RESPIRATION ABNORMAL 26 26 7.70 2.20 1.28 3.79
SNEEZING 33 36 8.12 2.02 1.26 3.24
AXILLARY MASS 17 15 6.18 2.50 1.25 5.00
VACCINATION ERROR 17 15 6.18 2.50 1.25 5.00
AUTOPSY 12 9 5.43 2.94 1.24 6.97
CHROMATURIA 21 21 6.06 2.20 1.20 4.03
FLUID REPLACEMENT 9 6 4.53 3.31 1.18 9.29
ORAL PAIN 19 19 5.41 2.20 1.17 4.16
COSTOCHONDRITIS 21 22 5.43 2.10 1.16 3.82
LIMB INJURY 16 15 5.10 2.35 1.16 4.75
VAGINAL HAEMORRHAGE 18 19 4.46 2.09 1.10 3.98
BODY TEMPERATURE DECREASED 15 15 4.10 2.20 1.08 4.51
SKIN BURNING SENSATION 15 15 4.10 2.20 1.08 4.51
FEELING HOT 337 368 90.52 2.02 1.74 2.34
SENSATION OF FOREIGN BODY 28 30 7.10 2.06 1.23 3.44
OBESITY 21 21 6.06 2.20 1.20 4.03
TROPONIN INCREASED 132 1 284.13 290.92 40.68 2080.49
ELECTROCARDIOGRAM ST SEGMENT ELEVATION 124 2 262.38 136.64 33.80 552.43
BELL'S PALSY 76 2 156.44 83.75 20.57 340.96
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN 52 1 107.48 114.60 15.84 828.94
ANOSMIA 57 2 114.60 62.81 15.34 257.25
BLOOD PRESSURE SYSTOLIC INCREASED 42 1 85.45 92.57 12.74 672.51
DRUG INEFFECTIVE 42 1 85.45 92.57 12.74 672.51
VENTRICULAR TACHYCARDIA 41 2 79.48 45.18 10.93 186.77
POOR QUALITY PRODUCT ADMINISTERED 36 1 72.26 79.34 10.88 578.65
TROPONIN I INCREASED 36 1 72.26 79.34 10.88 578.65
MITRAL VALVE INCOMPETENCE 33 1 65.66 72.73 9.95 531.73
EXPOSURE TO SARS-COV-2 33 2 61.98 36.36 8.73 151.53
VACCINE BREAKTHROUGH INFECTION 27 1 52.49 59.51 8.09 437.88
EPINEPHRINE 26 1 50.30 57.30 7.78 422.24
COVID-19 IMMUNISATION 24 1 45.92 52.89 7.16 390.96
TASTE DISORDER 27 2 48.92 29.75 7.08 125.11
GENITAL ULCERATION 21 1 39.36 46.28 6.23 344.05
BLOOD PRESSURE DIASTOLIC INCREASED 19 1 35.00 41.87 5.61 312.78
VULVAL ULCERATION 21 2 35.95 23.14 5.43 98.68
VULVOVAGINAL PAIN 20 2 33.80 22.04 5.15 94.28
BLOOD PRESSURE DIASTOLIC DECREASED 14 1 24.15 30.86 4.06 234.63
GENERAL PHYSICAL CONDITION ABNORMAL 14 1 24.15 30.86 4.06 234.63
ELECTROCARDIOGRAM ABNORMAL 14 2 21.07 15.43 3.51 67.87
C-REACTIVE PROTEIN INCREASED 13 2 18.98 14.33 3.23 63.48
SEDATION 10 1 15.59 22.04 2.82 172.16
APPENDICITIS PERFORATED 9 1 13.48 19.84 2.51 156.55
GENITAL PAIN 9 1 13.48 19.84 2.51 156.55
PULMONARY VALVE INCOMPETENCE 9 1 13.48 19.84 2.51 156.55
ISCHAEMIC STROKE 10 2 12.86 11.02 2.41 50.29
ASPARTATE AMINOTRANSFERASE INCREASED 8 1 11.39 17.63 2.21 140.96
ELECTRIC SHOCK SENSATION 8 1 11.39 17.63 2.21 140.96
BLOOD PRESSURE MEASUREMENT 9 2 10.87 9.92 2.14 45.90
BUNDLE BRANCH BLOCK RIGHT 9 2 10.87 9.92 2.14 45.90
SYSTOLIC DYSFUNCTION 7 1 9.33 15.43 1.90 125.38
VITAL SIGNS MEASUREMENT 7 1 9.33 15.43 1.90 125.38
VULVOVAGINAL SWELLING 8 2 8.93 8.82 1.87 41.51
EAR PRURITUS 7 2 7.05 7.71 1.60 37.13
HYPOMENORRHOEA 7 2 7.05 7.71 1.60 37.13
RED BLOOD CELL SEDIMENTATION RATE INCREASED 7 2 7.05 7.71 1.60 37.13
ANTIBIOTIC THERAPY 6 1 7.31 13.22 1.59 109.83
IGA NEPHROPATHY 6 1 7.31 13.22 1.59 109.83
SLEEP TERROR 6 1 7.31 13.22 1.59 109.83
THROMBOLYSIS 6 1 7.31 13.22 1.59 109.83
EYE HAEMORRHAGE 6 2 5.25 6.61 1.33 32.76
SOLILOQUY 6 2 5.25 6.61 1.33 32.76
ABDOMINAL LYMPHADENOPATHY 5 1 5.36 11.02 1.29 94.32
BEHAVIOUR DISORDER 5 1 5.36 11.02 1.29 94.32
CEREBRAL VENOUS SINUS THROMBOSIS 5 1 5.36 11.02 1.29 94.32
KAWASAKI'S DISEASE 5 1 5.36 11.02 1.29 94.32
OTORRHOEA 5 1 5.36 11.02 1.29 94.32
PNEUMONITIS 5 1 5.36 11.02 1.29 94.32
THROMBOTIC THROMBOCYTOPENIC PURPURA 5 1 5.36 11.02 1.29 94.32
VENTRICULAR FIBRILLATION 5 1 5.36 11.02 1.29 94.32
  • PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
  • For Current Week and Past Week Comparison
  • Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
  • Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
  • AGES 18+ YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
  • Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
  • N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
  • MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
  • AGES 18+ YEARS excludes missing ages
MedDRA Codes ALL Reports (18+) 12/14/2020-03/18/2022 COVID19 mRNA N=618096 01/01/2009-03/18/2022 NON-COVID19 N=282143 12/14-03/18 Chi-Square 12/14-03/18 PRR 12/14-03/18 LCL 12/14-03/18 UCL
COVID-19 PNEUMONIA 4021 9 1820.16 203.94 106.04 392.24
COVID-19 33319 138 15445.40 110.21 93.25 130.26
EXPOSURE TO SARS-COV-2 1779 4 802.42 203.02 76.11 541.51
VACCINE BREAKTHROUGH INFECTION 3267 14 1461.07 106.52 63.02 180.06
ASYMPTOMATIC COVID-19 958 3 428.99 145.77 46.93 452.76
LUNG OPACITY 1606 8 713.47 91.64 45.75 183.55
HEAVY MENSTRUAL BLEEDING 4144 30 1825.97 63.05 44.03 90.30
VACCINATION SITE PRURITUS 3933 29 1731.25 61.91 42.96 89.20
SARS-COV-2 TEST POSITIVE 869 3 388.29 132.22 42.56 410.77
POOR QUALITY PRODUCT ADMINISTERED 920 4 409.19 104.99 39.32 280.32
INTERMENSTRUAL BLEEDING 1292 8 569.73 73.72 36.79 147.73
PRODUCT DOSE OMISSION ISSUE 1692 13 740.86 59.41 34.43 102.53
INTERCHANGE OF VACCINE PRODUCTS 8227 94 3560.92 39.95 32.60 48.96
DYSMENORRHOEA 1778 25 751.92 32.46 21.88 48.18
PULMONARY THROMBOSIS 574 5 248.68 52.40 21.73 126.38
POSTMENOPAUSAL HAEMORRHAGE 505 4 219.54 57.63 21.55 154.14
POLYMENORRHOEA 678 7 291.44 44.21 21.00 93.09
POSITIVE AIRWAY PRESSURE THERAPY 658 7 282.31 42.91 20.38 90.36
MENSTRUATION IRREGULAR 3149 59 1300.80 24.36 18.83 31.52
SUSPECTED COVID-19 495 5 212.61 45.19 18.73 109.05
MENSTRUAL DISORDER 2409 44 996.56 24.99 18.55 33.67
ANOSMIA 3424 69 1403.88 22.65 17.85 28.75
ILLNESS 4113 85 1683.15 22.09 17.82 27.38
PRODUCT TEMPERATURE EXCURSION ISSUE 573 7 243.51 37.37 17.73 78.73
OLIGOMENORRHOEA 542 7 229.37 35.34 16.77 74.49
ANTICOAGULANT THERAPY 3320 83 1324.67 18.26 14.69 22.70
POST-ACUTE COVID-19 SYNDROME 292 3 124.70 44.43 14.25 138.56
TASTE DISORDER 2055 57 805.74 16.46 12.65 21.41
THROMBECTOMY 317 5 131.45 28.94 11.96 70.01
VACCINATION SITE URTICARIA 318 6 129.62 24.19 10.79 54.26
MATERNAL EXPOSURE DURING BREAST FEEDING 286 5 117.33 26.11 10.79 63.21
MECHANICAL URTICARIA 756 21 295.07 16.43 10.65 25.35
DRUG INEFFECTIVE 1239 40 472.48 14.14 10.32 19.37
IMMUNISATION 2723 99 1017.82 12.56 10.27 15.34
BELL'S PALSY 3090 114 1152.12 12.37 10.26 14.92
VACCINATION SITE MASS 1159 38 440.59 13.92 10.08 19.23
VACCINATION SITE ERYTHEMA 6111 246 2244.01 11.34 9.98 12.88
MENSTRUATION DELAYED 1073 37 403.83 13.24 9.54 18.37
AGEUSIA 4276 178 1554.10 10.97 9.44 12.74
APPENDICITIS 615 19 235.55 14.78 9.36 23.32
THROMBOSIS 3029 125 1101.20 11.06 9.25 13.23
PULMONARY EMBOLISM 2915 132 1035.18 10.08 8.47 12.00
THROAT CLEARING 398 13 150.41 13.98 8.04 24.28
PRODUCT USE ISSUE 454 16 169.26 12.95 7.87 21.32
EPINEPHRINE 386 13 144.99 13.55 7.80 23.55
ELECTRIC SHOCK SENSATION 792 33 285.59 10.96 7.73 15.52
PAROSMIA 1280 60 448.80 9.74 7.52 12.62
OFF LABEL USE 1165 55 407.51 9.67 7.38 12.67
BLOOD PRESSURE DIASTOLIC INCREASED 217 6 83.76 16.51 7.34 37.15
VACCINATION SITE MOVEMENT IMPAIRMENT 341 12 126.83 12.97 7.29 23.07
VITAL SIGNS MEASUREMENT 149 3 59.57 22.67 7.23 71.09
FACIAL DISCOMFORT 311 11 115.43 12.91 7.07 23.55
CARDIAC FLUTTER 1247 66 421.90 8.62 6.73 11.05
LEFT VENTRICULAR FAILURE 196 6 74.26 14.91 6.62 33.60
OROPHARYNGEAL DISCOMFORT 1471 82 489.79 8.19 6.56 10.23
BLOOD PRESSURE MEASUREMENT 193 6 72.91 14.68 6.52 33.09
DEATH 8445 617 2559.10 6.25 5.76 6.78
SYMPTOM RECURRENCE 119 3 45.97 18.11 5.76 56.94
DEEP VEIN THROMBOSIS 2078 139 648.03 6.82 5.75 8.10
THERAPEUTIC RESPONSE UNEXPECTED 486 26 162.99 8.53 5.75 12.66
INFUSION 170 6 62.53 12.93 5.73 29.19
PHARYNGEAL PARAESTHESIA 935 58 299.21 7.36 5.64 9.59
DEVICE CONNECTION ISSUE 342 17 116.91 9.18 5.64 14.95
PHARYNGEAL SWELLING 4276 310 1293.19 6.30 5.61 7.07
HYPERVOLAEMIA 183 7 66.27 11.93 5.61 25.39
SUPPRESSED LACTATION 131 4 49.22 14.95 5.53 40.43
ACCIDENTAL OVERDOSE 274 13 94.66 9.62 5.52 16.78
PREMENSTRUAL SYNDROME 145 5 53.40 13.24 5.43 32.28
VACCINATION SITE PAIN 14096 1120 4135.06 5.75 5.41 6.10
VACCINATION SITE RASH 2493 187 740.33 6.09 5.25 7.06
BLOOD LOSS ANAEMIA 137 5 49.80 12.51 5.12 30.53
CARDIAC FAILURE ACUTE 263 14 87.76 8.58 5.01 14.68
APPENDICECTOMY 460 29 145.63 7.24 4.98 10.54
OPHTHALMIC MIGRAINE 103 3 38.73 15.67 4.97 49.39
HYPOMENORRHOEA 161 7 56.41 10.50 4.93 22.38
CARDIAC DISCOMFORT 324 19 104.96 7.78 4.90 12.36
CHRONIC SPONTANEOUS URTICARIA 130 5 46.65 11.87 4.86 28.99
STENT PLACEMENT 276 16 89.59 7.87 4.76 13.03
IMMUNE THROMBOCYTOPENIA 337 21 106.83 7.33 4.71 11.38
TONGUE DISCOMFORT 589 42 177.66 6.40 4.68 8.75
PRODUCT PREPARATION ISSUE 2269 194 630.83 5.34 4.61 6.18
GENERAL PHYSICAL CONDITION ABNORMAL 287 18 90.58 7.28 4.52 11.72
PULMONARY INFARCTION 121 5 42.62 11.05 4.52 27.02
BREAST FEEDING 107 4 38.41 12.21 4.50 33.13
ACUTE RESPIRATORY FAILURE 3178 290 853.20 5.00 4.44 5.64
END STAGE RENAL DISEASE 144 7 48.82 9.39 4.40 20.05
ACUTE LEFT VENTRICULAR FAILURE 118 5 41.27 10.77 4.40 26.36
BODY TEMPERATURE ABNORMAL 169 9 55.95 8.57 4.38 16.76
TONGUE PRURITUS 495 38 144.16 5.95 4.28 8.27
TINNITUS 12721 1284 3249.24 4.52 4.27 4.79
BLOOD PRESSURE SYSTOLIC INCREASED 476 37 137.75 5.87 4.20 8.21
HEART RATE 125 6 42.37 9.51 4.19 21.57
HYPERAESTHESIA TEETH 149 8 49.05 8.50 4.17 17.31
ISCHAEMIC STROKE 460 36 132.64 5.83 4.15 8.19
DRAINAGE 202 13 62.77 7.09 4.05 12.43
ENERGY INCREASED 168 10 53.55 7.67 4.05 14.51
CORONARY ARTERIAL STENT INSERTION 244 17 73.64 6.55 4.01 10.71
TROPONIN INCREASED 360 28 103.87 5.87 4.00 8.62
CEREBROVASCULAR ACCIDENT 2889 294 724.27 4.49 3.98 5.06
SITTING DISABILITY 142 8 45.96 8.10 3.97 16.52
HOSPICE CARE 219 15 66.45 6.66 3.95 11.24
SUPERINFECTION 82 3 29.28 12.48 3.94 39.49
OXYGEN SATURATION DECREASED 2710 284 665.79 4.36 3.85 4.92
AMENORRHOEA 656 60 174.50 4.99 3.83 6.50
ACUTE MYOCARDIAL INFARCTION 1281 128 323.82 4.57 3.81 5.48
CHRONIC LEFT VENTRICULAR FAILURE 125 7 40.39 8.15 3.81 17.45
ELECTROCARDIOGRAM ST SEGMENT ELEVATION 260 20 75.09 5.93 3.77 9.35
IMMUNODEFICIENCY 578 53 153.38 4.98 3.76 6.59
HYPOXIA 3423 376 814.25 4.16 3.74 4.62
PULMONARY PAIN 477 43 127.64 5.06 3.71 6.92
CORONARY ARTERY OCCLUSION 185 13 55.35 6.50 3.70 11.40
DYSPNOEA AT REST 88 4 29.91 10.04 3.69 27.35
VACCINATION SITE DISCOMFORT 283 23 79.64 5.62 3.67 8.59
VENTRICULAR HYPOKINESIA 142 9 44.04 7.20 3.67 14.13
BREAST MASS 396 35 106.97 5.16 3.66 7.30
HAEMORRHAGE URINARY TRACT 131 8 41.11 7.47 3.66 15.26
CEREBRAL INFARCTION 396 36 105.26 5.02 3.57 7.06
AUTOPSY 322 28 87.56 5.25 3.57 7.72
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 8882 1072 1978.48 3.78 3.55 4.03
EXTRASYSTOLES 553 54 141.16 4.67 3.54 6.18
CLUSTER HEADACHE 126 8 38.92 7.19 3.52 14.69
PRODUCT STORAGE ERROR 13555 1675 2978.41 3.69 3.51 3.89
HEART RATE ABNORMAL 468 45 120.45 4.75 3.50 6.45
PERCUTANEOUS CORONARY INTERVENTION 73 3 25.25 11.11 3.50 35.24
LUNG INFILTRATION 1004 108 241.04 4.24 3.48 5.17
CARDIAC FAILURE 578 58 145.02 4.55 3.47 5.96
VACCINATION SITE HAEMORRHAGE 229 19 63.55 5.50 3.45 8.78
OXYGEN SATURATION 93 5 30.15 8.49 3.45 20.88
HEAD DISCOMFORT 2846 340 633.82 3.82 3.41 4.28
LUNG CONSOLIDATION 298 27 79.09 5.04 3.40 7.47
MENOPAUSE 122 8 37.17 6.96 3.40 14.23
GENERAL PHYSICAL HEALTH DETERIORATION 876 96 207.34 4.17 3.37 5.14
NEAR DEATH EXPERIENCE 140 10 41.31 6.39 3.36 12.14
MYOCARDIAL INFARCTION 1479 172 335.52 3.93 3.35 4.60
PULSELESS ELECTRICAL ACTIVITY 294 27 77.40 4.97 3.35 7.37
HOSPITALISATION 149 11 43.39 6.18 3.35 11.41
BLOOD GLUCOSE DECREASED 309 29 80.35 4.86 3.32 7.12
FIBRIN D DIMER INCREASED 138 10 40.44 6.30 3.32 11.97
APPENDICITIS PERFORATED 109 7 33.36 7.11 3.31 15.26
PERIORBITAL SWELLING 691 76 162.87 4.15 3.28 5.26
PNEUMONIA VIRAL 155 12 44.18 5.90 3.28 10.61
BLOOD PRESSURE DIASTOLIC DECREASED 108 7 32.92 7.04 3.28 15.13
EUPHORIC MOOD 260 24 68.11 4.95 3.26 7.51
CARDIAC ASSISTANCE DEVICE USER 78 4 25.47 8.90 3.26 24.31
ANGINA PECTORIS 1006 117 227.76 3.92 3.24 4.75
RESPIRATORY RATE DECREASED 293 28 75.29 4.78 3.24 7.04
PERICARDIAL EFFUSION 738 83 171.15 4.06 3.23 5.09
MULTIPLE ORGAN DYSFUNCTION SYNDROME 241 22 63.47 5.00 3.23 7.74
PARANASAL SINUS DISCOMFORT 843 97 192.27 3.97 3.22 4.89
EMBOLIC STROKE 87 5 27.50 7.94 3.22 19.56
BRADYKINESIA 170 14 47.07 5.54 3.21 9.56
CARDIO-RESPIRATORY ARREST 597 66 140.03 4.13 3.20 5.32
CARDIAC ARREST 1453 178 315.90 3.73 3.19 4.35
MYOCARDITIS 1905 240 404.84 3.62 3.17 4.14
ADNEXA UTERI PAIN 132 10 37.85 6.03 3.17 11.46
DEMENTIA 396 42 95.35 4.30 3.13 5.92
BREAST SWELLING 724 85 162.37 3.89 3.11 4.87
ATYPICAL PNEUMONIA 120 9 34.47 6.09 3.09 11.98
PNEUMONIA BACTERIAL 309 32 75.41 4.41 3.06 6.34
SENSITIVE SKIN 1247 158 263.15 3.60 3.05 4.25
BREAST TENDERNESS 515 59 117.43 3.98 3.04 5.22
VACCINATION SITE DISCOLOURATION 330 35 79.28 4.30 3.04 6.10
BLOOD DISORDER 73 4 23.26 8.33 3.04 22.79
GIANT CELL ARTERITIS 63 3 20.80 9.59 3.01 30.52
EXPIRED PRODUCT ADMINISTERED 13906 2018 2624.54 3.15 3.00 3.30
CHRONIC KIDNEY DISEASE 530 62 118.91 3.90 3.00 5.08
HAEMOGLOBIN DECREASED 99 7 29.01 6.46 3.00 13.89
ACUTE KIDNEY INJURY 2324 315 462.24 3.37 2.99 3.79
CARDIOGENIC SHOCK 230 23 57.19 4.56 2.97 7.01
LYMPHADENOPATHY 21469 3194 3984.59 3.07 2.96 3.18
VENTRICULAR EXTRASYSTOLES 952 124 195.68 3.50 2.91 4.23
CEREBRAL HAEMORRHAGE 398 46 89.90 3.95 2.91 5.36
EAR DISCOMFORT 2537 359 483.68 3.23 2.89 3.60
BLOOD PRESSURE ABNORMAL 521 64 112.27 3.72 2.87 4.82
OCULAR DISCOMFORT 855 112 174.71 3.48 2.86 4.24
BLOOD PRESSURE SYSTOLIC DECREASED 86 6 25.20 6.54 2.86 14.97
SINUS RHYTHM 60 3 19.47 9.13 2.86 29.11
PERICARDITIS 1582 220 306.26 3.28 2.85 3.78
CARDIAC ABLATION 135 12 35.63 5.14 2.85 9.27
PALPITATIONS 14184 2190 2500.77 2.96 2.83 3.09
IMPAIRED SELF-CARE 85 6 24.76 6.47 2.83 14.80
RETINAL VEIN OCCLUSION 93 7 26.42 6.06 2.81 13.07
CARDIAC DISORDER 849 114 169.50 3.40 2.80 4.13
ATRIAL FIBRILLATION 3305 498 590.02 3.03 2.76 3.33
HYPERTENSIVE EMERGENCY 83 6 23.90 6.31 2.76 14.46
CORONARY ARTERY THROMBOSIS 57 3 18.14 8.67 2.72 27.69
LYMPH NODE PAIN 5200 815 889.93 2.91 2.71 3.14
SWELLING OF EYELID 1096 157 205.46 3.19 2.70 3.77
EJECTION FRACTION DECREASED 194 21 45.52 4.22 2.69 6.61
ATRIOVENTRICULAR BLOCK COMPLETE 81 6 23.04 6.16 2.69 14.12
TONGUE ERYTHEMA 135 13 33.96 4.74 2.68 8.37
UTERINE PAIN 56 3 17.70 8.52 2.67 27.22
RETINAL ARTERY OCCLUSION 96 8 25.94 5.48 2.66 11.27
EPISTAXIS 1956 298 343.94 3.00 2.65 3.38
PLATELET COUNT DECREASED 282 34 61.27 3.79 2.65 5.40
EYE HAEMORRHAGE 287 35 61.78 3.74 2.64 5.32
RESPIRATORY RATE INCREASED 1364 204 244.42 3.05 2.63 3.54
RESUSCITATION 1009 148 184.38 3.11 2.62 3.70
GASTROINTESTINAL WALL THICKENING 55 3 17.26 8.37 2.62 26.75
DYSPNOEA EXERTIONAL 2024 314 348.62 2.94 2.61 3.31
PULSE ABSENT 604 84 116.23 3.28 2.61 4.12
BLOOD URINE PRESENT 590 82 113.58 3.28 2.61 4.14
SLEEP DEFICIT 94 8 25.09 5.36 2.61 11.04
MIGRAINE 7986 1322 1282.96 2.76 2.60 2.92
VEIN DISORDER 131 13 32.29 4.60 2.60 8.13
LUNG DISORDER 567 79 108.85 3.28 2.59 4.15
ARRHYTHMIA 1082 162 193.41 3.05 2.58 3.60
DISORGANISED SPEECH 130 13 31.88 4.56 2.58 8.07
BREAST DISCOMFORT 115 11 28.90 4.77 2.57 8.86
BREAST DISCHARGE 62 4 18.45 7.08 2.57 19.45
LYMPHADENOPATHY MEDIASTINAL 107 10 27.20 4.88 2.55 9.34
GENERAL SYMPTOM 135 14 32.34 4.40 2.54 7.63
INJECTION SITE LYMPHADENOPATHY 121 12 29.76 4.60 2.54 8.33
HEART RATE IRREGULAR 1922 308 318.41 2.85 2.53 3.21
VAGINAL HAEMORRHAGE 1515 238 256.75 2.91 2.53 3.33
THALAMIC INFARCTION 61 4 18.01 6.96 2.53 19.14
CARDIOVERSION 483 68 91.61 3.24 2.52 4.18
DEMENTIA ALZHEIMER'S TYPE 120 12 29.35 4.56 2.52 8.26
HORMONE LEVEL ABNORMAL 98 9 25.09 4.97 2.51 9.84
VACCINATION SITE INDURATION 1183 185 201.30 2.92 2.50 3.41
CARDIOMEGALY 785 118 139.42 3.04 2.50 3.68
FEAR OF INJECTION 227 28 48.20 3.70 2.50 5.48
BREAST CYST 68 5 19.23 6.21 2.50 15.39
PANIC ATTACK 1206 190 203.44 2.90 2.49 3.38
SUDDEN DEATH 158 18 35.49 4.01 2.46 6.52
HEART RATE DECREASED 1368 221 224.00 2.83 2.45 3.26
PHARYNGEAL HYPOAESTHESIA 465 67 86.07 3.17 2.45 4.09
BONE SWELLING 59 4 17.14 6.73 2.45 18.53
NEW DAILY PERSISTENT HEADACHE 59 4 17.14 6.73 2.45 18.53
HOT FLUSH 3413 585 520.23 2.66 2.44 2.91
URTICARIA CHRONIC 156 18 34.68 3.96 2.43 6.44
HYPERTENSIVE URGENCY 109 11 26.40 4.52 2.43 8.41
IMPAIRED QUALITY OF LIFE 102 10 25.12 4.66 2.43 8.91
NEOPLASM 88 8 22.56 5.02 2.43 10.35
CHEST PAIN 20468 3734 2925.75 2.50 2.42 2.59
PARAESTHESIA ORAL 6402 1136 934.44 2.57 2.42 2.74
PRODUCT ADMINISTRATION ERROR 684 105 118.50 2.97 2.42 3.65
THROMBOPHLEBITIS SUPERFICIAL 142 16 32.07 4.05 2.42 6.79
HEPATIC LESION 58 4 16.71 6.62 2.40 18.23
HILAR LYMPHADENOPATHY 58 4 16.71 6.62 2.40 18.23
BLOOD GLUCOSE INCREASED 832 132 138.86 2.88 2.39 3.46
BREAST ENLARGEMENT 65 5 17.94 5.93 2.39 14.74
VENTRICULAR FIBRILLATION 229 30 46.09 3.48 2.38 5.10
ACUTE CORONARY SYNDROME 79 7 20.45 5.15 2.38 11.16
VACCINATION SITE WARMTH 3259 576 476.02 2.58 2.36 2.82
SKIN SENSITISATION 171 21 36.21 3.72 2.36 5.85
MOUTH SWELLING 924 151 148.80 2.79 2.35 3.32
PULMONARY MASS 441 66 78.30 3.05 2.35 3.95
PULMONARY OEDEMA 722 116 118.54 2.84 2.34 3.46
DIVERTICULITIS 274 38 52.37 3.29 2.34 4.62
CONDITION AGGRAVATED 16496 3130 2208.41 2.41 2.32 2.50
VACCINATION SITE SWELLING 5152 948 711.76 2.48 2.32 2.66
BREAST PAIN 1895 332 279.40 2.61 2.32 2.93
JUGULAR VEIN DISTENSION 56 4 15.85 6.39 2.32 17.62
THROMBOLYSIS 56 4 15.85 6.39 2.32 17.62
BLOOD IRON DECREASED 49 3 14.64 7.46 2.32 23.92
VACCINATION SITE REACTION 1252 214 190.52 2.67 2.31 3.09
NIPPLE PAIN 116 13 26.13 4.07 2.30 7.23
FEEDING DISORDER 1379 242 202.51 2.60 2.27 2.98
DISCOLOURED VOMIT 48 3 14.20 7.30 2.27 23.45
HEART RATE INCREASED 13572 2626 1753.81 2.36 2.26 2.46
SEIZURE 3673 683 498.20 2.45 2.26 2.66
PERICARDIAL DRAINAGE 88 9 20.93 4.46 2.25 8.86
MENTAL FATIGUE 75 7 18.77 4.89 2.25 10.61
UTERINE SPASM 126 15 27.13 3.83 2.24 6.55
INCREASED VISCOSITY OF UPPER RESPIRATORY SECRETION 61 5 16.24 5.57 2.24 13.86
HAEMORRHAGIC STROKE 113 13 24.92 3.97 2.23 7.04
DIZZINESS EXERTIONAL 47 3 13.77 7.15 2.23 22.98
FEAR 793 136 119.77 2.66 2.22 3.19
NONINFECTIVE GINGIVITIS 87 9 20.52 4.41 2.22 8.76
INCORRECT PRODUCT FORMULATION ADMINISTERED 709 121 107.70 2.67 2.21 3.24
PALLIATIVE CARE 80 8 19.23 4.56 2.21 9.44
VERTIGO 7405 1451 929.08 2.33 2.20 2.46
SUPRAVENTRICULAR TACHYCARDIA 494 81 78.80 2.78 2.20 3.52
UNRESPONSIVE TO STIMULI 4105 792 525.71 2.37 2.19 2.55
TRANSIENT ISCHAEMIC ATTACK 724 125 108.28 2.64 2.19 3.20
VENTRICULAR TACHYCARDIA 362 57 60.47 2.90 2.19 3.83
NASAL DRYNESS 111 13 24.11 3.90 2.19 6.92
AUTOSCOPY 79 8 18.81 4.51 2.18 9.33
DYSGEUSIA 4104 804 512.52 2.33 2.16 2.51
LIP PRURITUS 368 59 60.15 2.85 2.16 3.75
SINUS PAIN 457 76 71.53 2.74 2.15 3.50
HEART VALVE INCOMPETENCE 65 6 16.24 4.95 2.14 11.41
MUSCLE DISCOMFORT 183 26 33.83 3.21 2.13 4.84
HYPERTENSION 7255 1477 852.10 2.24 2.12 2.37
IMPLANTABLE DEFIBRILLATOR INSERTION 77 8 17.99 4.39 2.12 9.10
FEELING ABNORMAL 21127 4426 2401.68 2.18 2.11 2.25
PLEURAL EFFUSION 1127 210 151.37 2.45 2.11 2.84
BLOOD PRESSURE FLUCTUATION 454 77 69.24 2.69 2.11 3.43
SUPRAVENTRICULAR EXTRASYSTOLES 252 39 42.70 2.95 2.11 4.13
RESPIRATORY SYMPTOM 300 48 49.01 2.85 2.10 3.87
ARTERIOSCLEROSIS CORONARY ARTERY 219 33 38.15 3.03 2.10 4.37
RENAL INFARCT 51 4 13.71 5.82 2.10 16.10
CROHN'S DISEASE 163 23 30.25 3.23 2.09 5.01
HEPATIC CIRRHOSIS 129 17 25.42 3.46 2.09 5.74
INCORRECT DOSE ADMINISTERED 4802 984 555.39 2.23 2.08 2.39
SKIN SWELLING 674 122 94.21 2.52 2.08 3.06
ASTHENOPIA 354 59 55.06 2.74 2.08 3.61
FATIGUE 94183 20429 11149.54 2.10 2.07 2.14
HYPOACUSIS 1331 257 169.13 2.36 2.07 2.70
RENAL PAIN 594 107 83.52 2.53 2.06 3.11
INCREASED APPETITE 87 10 18.98 3.97 2.06 7.64
PERIPHERAL ISCHAEMIA 50 4 13.28 5.71 2.06 15.80
CARDIAC FAILURE CONGESTIVE 1020 195 131.50 2.39 2.05 2.78
PNEUMONITIS 240 38 39.54 2.88 2.05 4.06
HYPOAESTHESIA ORAL 4612 964 514.24 2.18 2.04 2.34
INTERSTITIAL LUNG DISEASE 202 31 34.40 2.97 2.04 4.34
GAIT INABILITY 2291 470 263.19 2.23 2.02 2.46
ORAL DISCOMFORT 767 145 100.45 2.41 2.02 2.88
VACCINATION SITE BRUISING 508 92 70.75 2.52 2.02 3.15
LUNG HYPERINFLATION 49 4 12.86 5.59 2.02 15.49
MOVEMENT DISORDER 1714 347 201.28 2.25 2.01 2.53
ABNORMAL DREAMS 501 91 69.46 2.51 2.01 3.14
SUDDEN CARDIAC DEATH 61 6 14.58 4.64 2.01 10.73
APHASIA 1917 394 219.27 2.22 1.99 2.48
DIABETIC KETOACIDOSIS 171 26 29.30 3.00 1.99 4.54
METAMORPHOPSIA 139 20 25.15 3.17 1.99 5.07
ALOPECIA 1246 251 147.33 2.27 1.98 2.59
CHEST DISCOMFORT 15010 3348 1494.74 2.05 1.97 2.12
BLOOD PRESSURE INCREASED 7806 1719 789.99 2.07 1.97 2.18
SMALL INTESTINAL OBSTRUCTION 138 20 24.77 3.15 1.97 5.03
HYPERTENSIVE HEART DISEASE 189 30 30.87 2.88 1.96 4.23
TOXIC ENCEPHALOPATHY 99 13 19.36 3.48 1.95 6.20
VASCULAR PAIN 99 13 19.36 3.48 1.95 6.20
FACIAL PARALYSIS 2662 572 280.55 2.12 1.94 2.32
ACUTE RESPIRATORY DISTRESS SYNDROME 360 65 50.14 2.53 1.94 3.29
CORONARY ARTERY DISEASE 590 114 74.42 2.36 1.93 2.89
GASTROINTESTINAL HAEMORRHAGE 386 71 52.34 2.48 1.93 3.20
SINUS OPERATION 212 35 33.06 2.76 1.93 3.95
ASCITES 166 26 27.45 2.91 1.93 4.41
CARDIAC TAMPONADE 76 9 16.06 3.85 1.93 7.69
VASODILATATION 140 21 24.21 3.04 1.92 4.81
HUNGER 190 31 29.99 2.80 1.91 4.09
HYPOGEUSIA 139 21 23.84 3.02 1.91 4.78
THYROIDITIS 75 9 15.67 3.80 1.91 7.59
TACHYPNOEA 1220 256 133.95 2.18 1.90 2.49
SEDATION 203 34 31.03 2.73 1.90 3.92
HYPOAESTHESIA EYE 159 25 26.14 2.90 1.90 4.43
PSORIATIC ARTHROPATHY 91 12 17.66 3.46 1.90 6.32
DENTAL DISCOMFORT 52 5 12.46 4.75 1.90 11.88
DEAFNESS 1283 272 138.19 2.15 1.89 2.45
EAR SWELLING 503 98 62.48 2.34 1.89 2.91
DISCHARGE 96 13 18.20 3.37 1.89 6.02
CHEST INJURY 46 4 11.60 5.25 1.89 14.58
THYROIDITIS SUBACUTE 46 4 11.60 5.25 1.89 14.58
DIALYSIS 216 37 32.09 2.66 1.88 3.78
CARDITIS 74 9 15.27 3.75 1.88 7.50
CEREBRAL VENOUS THROMBOSIS 40 3 10.76 6.09 1.88 19.67
INSULIN THERAPY 40 3 10.76 6.09 1.88 19.67
RENAL IMPAIRMENT 338 63 44.82 2.45 1.87 3.20
SUBARACHNOID HAEMORRHAGE 176 29 27.38 2.77 1.87 4.10
SUBDURAL HAEMATOMA 136 21 22.72 2.96 1.87 4.68
HEPATIC PAIN 95 13 17.82 3.34 1.87 5.96
ARTERIAL OCCLUSIVE DISEASE 68 8 14.35 3.88 1.87 8.07
BREAST CANCER 51 5 12.05 4.66 1.86 11.67
SYSTOLIC DYSFUNCTION 51 5 12.05 4.66 1.86 11.67
VENTRICULAR HYPERTROPHY 51 5 12.05 4.66 1.86 11.67
DRY THROAT 816 171 89.55 2.18 1.85 2.57
COLITIS 292 54 39.09 2.47 1.85 3.30
BLADDER PAIN 89 12 16.88 3.39 1.85 6.19
LEFT ATRIAL ENLARGEMENT 73 9 14.87 3.70 1.85 7.40
PULMONARY FIBROSIS 173 29 26.30 2.72 1.84 4.04
NERVOUSNESS 2087 472 197.74 2.02 1.83 2.23
LYMPHOEDEMA 281 52 37.55 2.47 1.83 3.32
LACUNAR INFARCTION 98 14 17.61 3.20 1.83 5.59
HYPOOSMOLAR STATE 39 3 10.33 5.93 1.83 19.20
ABDOMINAL PAIN LOWER 859 184 90.44 2.13 1.82 2.50
RED BLOOD CELL SEDIMENTATION RATE INCREASED 50 5 11.64 4.56 1.82 11.45
VITREOUS FLOATERS 519 106 59.44 2.23 1.81 2.75
APHTHOUS ULCER 298 57 37.85 2.39 1.80 3.17
THYROID MASS 131 21 20.89 2.85 1.80 4.51
CORONARY ARTERY STENOSIS 71 9 14.09 3.60 1.80 7.20
MENOMETRORRHAGIA 44 4 10.76 5.02 1.80 13.97
COSTOCHONDRITIS 215 39 29.44 2.52 1.79 3.54
BRAIN INJURY 150 25 22.87 2.74 1.79 4.18
LUNG NEOPLASM MALIGNANT 86 12 15.73 3.27 1.79 5.98
SEPTIC SHOCK 492 102 54.80 2.20 1.78 2.72
GINGIVAL BLEEDING 259 49 33.38 2.41 1.78 3.27
ANGIOPLASTY 65 8 13.16 3.71 1.78 7.73
SPLENIC INFARCTION 49 5 11.23 4.47 1.78 11.23
VACCINATION SITE DISCHARGE 49 5 11.23 4.47 1.78 11.23
ARTERIOSCLEROSIS 460 95 51.55 2.21 1.77 2.76
ATRIAL FLUTTER 298 58 36.78 2.35 1.77 3.11
POLYURIA 249 47 32.18 2.42 1.77 3.30
LEFT VENTRICULAR DYSFUNCTION 185 33 25.86 2.56 1.77 3.71
OXYGEN SATURATION ABNORMAL 70 9 13.70 3.55 1.77 7.11
ANGINA UNSTABLE 54 6 11.73 4.11 1.77 9.55
HAEMATOCHEZIA 586 125 61.97 2.14 1.76 2.60
BOWEL MOVEMENT IRREGULARITY 216 40 28.67 2.46 1.76 3.45
HAEMORRHAGE INTRACRANIAL 124 20 19.58 2.83 1.76 4.54
ATRIAL ENLARGEMENT 43 4 10.35 4.91 1.76 13.67
ISCHAEMIC CEREBRAL INFARCTION 43 4 10.35 4.91 1.76 13.67
NEUROLOGICAL SYMPTOM 730 161 72.38 2.07 1.75 2.45
MUSCLE STRENGTH ABNORMAL 89 13 15.54 3.13 1.75 5.59
AXILLARY MASS 840 188 80.88 2.04 1.74 2.39
BLEPHAROSPASM 546 117 57.18 2.13 1.74 2.60
BODY TEMPERATURE FLUCTUATION 232 44 29.71 2.41 1.74 3.32
APPETITE DISORDER 113 18 18.05 2.87 1.74 4.71
POOR PERIPHERAL CIRCULATION 108 17 17.47 2.90 1.74 4.84
THERMAL BURN 103 16 16.89 2.94 1.74 4.98
CORONARY ANGIOPLASTY 37 3 9.49 5.63 1.74 18.26
IMMUNE-MEDIATED ADVERSE REACTION 37 3 9.49 5.63 1.74 18.26
TENSION HEADACHE 360 74 40.54 2.22 1.73 2.85
CHEST TUBE INSERTION 126 21 19.09 2.74 1.73 4.35
COMA SCALE ABNORMAL 98 15 16.31 2.98 1.73 5.14
BLOOD GLUCOSE ABNORMAL 88 13 15.17 3.09 1.73 5.53
IRREGULAR BREATHING 73 10 13.48 3.33 1.72 6.45
MYOCARDIAL OEDEMA 42 4 9.94 4.79 1.72 13.37
RIGHT VENTRICULAR FAILURE 42 4 9.94 4.79 1.72 13.37
GLOSSITIS 139 24 20.15 2.64 1.71 4.08
BASEDOW'S DISEASE 125 21 18.73 2.72 1.71 4.31
EYE CONTUSION 125 21 18.73 2.72 1.71 4.31
FOOD AVERSION 47 5 10.42 4.29 1.71 10.79
HYPERKALAEMIA 308 63 34.90 2.23 1.70 2.93
DISSOCIATION 133 23 19.21 2.64 1.70 4.11
ACUTE PULMONARY OEDEMA 57 7 11.45 3.72 1.70 8.15
BILIARY COLIC 52 6 10.93 3.96 1.70 9.21
FEELING DRUNK 335 70 36.56 2.18 1.69 2.83
EAR DISORDER 146 26 20.30 2.56 1.69 3.89
TESTICULAR PAIN 193 37 24.17 2.38 1.68 3.38
MOTION SICKNESS 189 36 23.91 2.40 1.68 3.42
HYPOTHERMIA 145 26 19.95 2.55 1.68 3.86
ISCHAEMIA 95 15 15.21 2.89 1.68 4.98
WHITE BLOOD CELL COUNT DECREASED 81 12 13.85 3.08 1.68 5.65
BLOOD THYROID STIMULATING HORMONE INCREASED 41 4 9.52 4.68 1.68 13.06
MUCOSAL DISORDER 41 4 9.52 4.68 1.68 13.06
EMBOLISM 66 9 12.16 3.35 1.67 6.72
AUTOIMMUNE HEPATITIS 51 6 10.53 3.88 1.67 9.04
INFLAMMATORY MARKER INCREASED 46 5 10.02 4.20 1.67 10.57
CARDIOMYOPATHY 342 73 35.85 2.14 1.66 2.75
AORTIC ANEURYSM 103 17 15.66 2.77 1.66 4.62
HYPOSMIA 94 15 14.85 2.86 1.66 4.93
STRESS CARDIOMYOPATHY 80 12 13.48 3.04 1.66 5.58
HAEMOPTYSIS 454 101 43.97 2.05 1.65 2.55
PREGNANCY 279 58 30.63 2.20 1.65 2.91
HORDEOLUM 143 26 19.26 2.51 1.65 3.81
VACCINATION SITE VESICLES 89 14 14.27 2.90 1.65 5.10
MYOCARDIAL ISCHAEMIA 142 26 18.92 2.49 1.64 3.79
C-REACTIVE PROTEIN INCREASED 79 12 13.11 3.01 1.64 5.52
ESCHERICHIA BACTERAEMIA 35 3 8.65 5.33 1.64 17.32
ACQUIRED DIAPHRAGMATIC EVENTRATION 50 6 10.14 3.80 1.63 8.87
SHOCK HAEMORRHAGIC 40 4 9.12 4.56 1.63 12.76
COLITIS ULCERATIVE 178 35 21.32 2.32 1.62 3.34
HYPERTHYROIDISM 174 34 21.05 2.34 1.62 3.37
HIP FRACTURE 110 19 15.78 2.64 1.62 4.30
GASTROINTESTINAL INFLAMMATION 78 12 12.74 2.97 1.62 5.45
AORTIC STENOSIS 100 17 14.60 2.69 1.61 4.49
CHRONIC RESPIRATORY FAILURE 73 11 12.16 3.03 1.61 5.71
ISCHAEMIC CARDIOMYOPATHY 73 11 12.16 3.03 1.61 5.71
COAGULOPATHY 181 36 21.27 2.30 1.60 3.28
COMMUNICATION DISORDER 164 32 19.85 2.34 1.60 3.42
TYPE IV HYPERSENSITIVITY REACTION 129 24 16.71 2.45 1.59 3.79
COLITIS MICROSCOPIC 63 9 11.02 3.20 1.59 6.42
SKIN TEXTURE ABNORMAL 63 9 11.02 3.20 1.59 6.42
INTRAVENTRICULAR HAEMORRHAGE 44 5 9.22 4.02 1.59 10.13
CIRCUMORAL SWELLING 39 4 8.71 4.45 1.59 12.45
AORTIC VALVE STENOSIS 34 3 8.23 5.17 1.59 16.84
LANGUAGE DISORDER 34 3 8.23 5.17 1.59 16.84
ORAL LICHEN PLANUS 34 3 8.23 5.17 1.59 16.84
PULSE ABNORMAL 334 75 31.55 2.03 1.58 2.61
BUNDLE BRANCH BLOCK RIGHT 227 48 24.01 2.16 1.58 2.95
PALATAL SWELLING 81 13 12.59 2.84 1.58 5.11
ATRIOVENTRICULAR BLOCK 136 26 16.90 2.39 1.57 3.63
LIP ERYTHEMA 136 26 16.90 2.39 1.57 3.63
LIP DISORDER 123 23 15.77 2.44 1.56 3.81
JAW DISORDER 110 20 14.65 2.51 1.56 4.04
MAST CELL ACTIVATION SYNDROME 62 9 10.64 3.14 1.56 6.33
BREAST INFLAMMATION 48 6 9.35 3.65 1.56 8.53
CHOLECYSTITIS ACUTE 48 6 9.35 3.65 1.56 8.53
PUPIL FIXED 273 61 25.95 2.04 1.55 2.70
SPINAL STENOSIS 88 15 12.71 2.68 1.55 4.63
INTRACRANIAL ANEURYSM 66 10 10.85 3.01 1.55 5.86
BREATH SOUNDS ABSENT 38 4 8.30 4.34 1.55 12.15
NEPHROSCLEROSIS 38 4 8.30 4.34 1.55 12.15
THIRST DECREASED 38 4 8.30 4.34 1.55 12.15
HAEMATEMESIS 253 56 24.49 2.06 1.54 2.75
CONJUNCTIVAL HAEMORRHAGE 125 24 15.37 2.38 1.54 3.68
FAECES SOFT 96 17 13.20 2.58 1.54 4.32
ELECTROCARDIOGRAM T WAVE INVERSION 83 14 12.11 2.71 1.54 4.77
SKIN ODOUR ABNORMAL 79 13 11.88 2.77 1.54 4.99
DECREASED NASOLABIAL FOLD 33 3 7.82 5.02 1.54 16.37
INCORRECT PRODUCT ADMINISTRATION DURATION 33 3 7.82 5.02 1.54 16.37
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION 47 6 8.96 3.58 1.53 8.36
PULMONARY HYPERTENSION 215 47 21.26 2.09 1.52 2.86
NORMOCYTIC ANAEMIA 103 19 13.37 2.47 1.52 4.04
ANTIBIOTIC THERAPY 65 10 10.48 2.97 1.52 5.77
BLOOD URINE 42 5 8.42 3.83 1.52 9.69
FEEDING TUBE USER 42 5 8.42 3.83 1.52 9.69
PULMONARY HAEMORRHAGE 42 5 8.42 3.83 1.52 9.69
GINGIVAL SWELLING 224 50 21.23 2.04 1.51 2.78
SKIN WEEPING 131 26 15.26 2.30 1.51 3.50
PHYSICAL DECONDITIONING 115 22 14.17 2.39 1.51 3.76
CORONARY ARTERY BYPASS 90 16 12.26 2.57 1.51 4.37
BASAL GANGLIA INFARCTION 37 4 7.90 4.22 1.51 11.85
PERICARDIAL EXCISION 37 4 7.90 4.22 1.51 11.85
VACCINATION SITE JOINT PAIN 37 4 7.90 4.22 1.51 11.85
WRONG TECHNIQUE IN DEVICE USAGE PROCESS 37 4 7.90 4.22 1.51 11.85
USE OF ACCESSORY RESPIRATORY MUSCLES 138 28 15.50 2.25 1.50 3.38
PARKINSON'S DISEASE 106 20 13.30 2.42 1.50 3.90
CARDIOVASCULAR DISORDER 98 18 12.77 2.49 1.50 4.11
SLEEP TERROR 46 6 8.58 3.50 1.49 8.19
BLADDER SPASM 32 3 7.41 4.87 1.49 15.90
EPIDIDYMITIS 32 3 7.41 4.87 1.49 15.90
INNER EAR INFLAMMATION 32 3 7.41 4.87 1.49 15.90
PHANTOM LIMB SYNDROME 32 3 7.41 4.87 1.49 15.90
PANCREATITIS 216 49 19.75 2.01 1.48 2.74
POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME 206 46 19.46 2.04 1.48 2.81
MIDDLE EAR EFFUSION 201 45 18.87 2.04 1.48 2.82
ACCIDENTAL UNDERDOSE 194 43 18.58 2.06 1.48 2.87
HYPERCAPNIA 167 36 16.84 2.12 1.48 3.04
PATIENT ISOLATION 50 7 8.76 3.26 1.48 7.19
EMBOLISM VENOUS 41 5 8.03 3.74 1.48 9.47
SUFFOCATION FEELING 41 5 8.03 3.74 1.48 9.47
PANCREATITIS ACUTE 139 29 14.83 2.19 1.47 3.26
AORTIC DILATATION 54 8 8.96 3.08 1.47 6.47
FACIAL SPASM 103 20 12.31 2.35 1.46 3.79
MASTITIS 99 19 12.04 2.38 1.46 3.89
NASAL PRURITUS 87 16 11.24 2.48 1.46 4.23
MENIERE'S DISEASE 83 15 10.98 2.53 1.46 4.38
BRAIN HERNIATION 45 6 8.20 3.42 1.46 8.02
ORAL BLOOD BLISTER 45 6 8.20 3.42 1.46 8.02
PATIENT UNCOOPERATIVE 36 4 7.50 4.11 1.46 11.54
EMPHYSEMA 172 38 16.52 2.07 1.45 2.94
DIARRHOEA HAEMORRHAGIC 157 34 15.65 2.11 1.45 3.05
FAILURE TO THRIVE 134 28 14.23 2.18 1.45 3.28
HEART SOUNDS ABNORMAL 134 28 14.23 2.18 1.45 3.28
BRONCHIAL WALL THICKENING 49 7 8.38 3.20 1.45 7.05
HANGOVER 86 16 10.90 2.45 1.44 4.18
INTESTINAL ISCHAEMIA 53 8 8.59 3.02 1.44 6.36
CORONAVIRUS INFECTION 40 5 7.64 3.65 1.44 9.25
MEDICAL DIET 40 5 7.64 3.65 1.44 9.25
VEIN DISCOLOURATION 40 5 7.64 3.65 1.44 9.25
BODY HEIGHT 31 3 7.00 4.72 1.44 15.43
RENAL ATROPHY 31 3 7.00 4.72 1.44 15.43
DYSCHROMATOPSIA 57 9 8.81 2.89 1.43 5.84
HYPERCOAGULATION 57 9 8.81 2.89 1.43 5.84
BLOOD POTASSIUM DECREASED 81 15 10.30 2.46 1.42 4.28
PERIPHERAL ARTERIAL OCCLUSIVE DISEASE 48 7 8.01 3.13 1.42 6.92
ENTERAL NUTRITION 35 4 7.11 3.99 1.42 11.24
RIGHT ATRIAL DILATATION 35 4 7.11 3.99 1.42 11.24
CAROTID ARTERY OCCLUSION 56 9 8.45 2.84 1.41 5.74
INJECTION SITE MUSCLE WEAKNESS 64 11 8.93 2.66 1.40 5.04
ANGIOPATHY 60 10 8.69 2.74 1.40 5.35
VENOUS THROMBOSIS LIMB 39 5 7.26 3.56 1.40 9.03
ABNORMAL FAECES 136 30 12.97 2.07 1.39 3.07
MELAENA 136 30 12.97 2.07 1.39 3.07
ACIDOSIS 91 18 10.46 2.31 1.39 3.83
ANTIALLERGIC THERAPY 47 7 7.64 3.06 1.39 6.78
INFARCTION 47 7 7.64 3.06 1.39 6.78
PUPILLARY LIGHT REFLEX TESTS ABNORMAL 47 7 7.64 3.06 1.39 6.78
ADULT FAILURE TO THRIVE 43 6 7.44 3.27 1.39 7.69
CONTRACEPTION 43 6 7.44 3.27 1.39 7.69
CUTANEOUS VASCULITIS 43 6 7.44 3.27 1.39 7.69
HIP SURGERY 30 3 6.59 4.56 1.39 14.96
VARICOSE VEIN 109 23 11.24 2.16 1.38 3.39
VULVOVAGINAL PAIN 109 23 11.24 2.16 1.38 3.39
LIVER DISORDER 98 20 10.70 2.24 1.38 3.62
STENOSIS 34 4 6.71 3.88 1.38 10.93
FRUSTRATION TOLERANCE DECREASED 134 30 12.38 2.04 1.37 3.03
BLADDER DISCOMFORT 38 5 6.88 3.47 1.37 8.81
UTERINE LEIOMYOMA 115 25 11.21 2.10 1.36 3.24
PERITONITIS 42 6 7.07 3.20 1.36 7.52
FEBRILE NEUTROPENIA 50 8 7.50 2.85 1.35 6.02
WALKING DISABILITY 46 7 7.28 3.00 1.35 6.64
TRIGGER FINGER 113 25 10.61 2.06 1.34 3.18
VACCINATION SITE IRRITATION 65 12 8.17 2.47 1.34 4.58
VITILIGO 65 12 8.17 2.47 1.34 4.58
ANTIPHOSPHOLIPID SYNDROME 29 3 6.19 4.41 1.34 14.49
PANCREATIC CARCINOMA 29 3 6.19 4.41 1.34 14.49
CONGESTIVE CARDIOMYOPATHY 76 15 8.66 2.31 1.33 4.02
THROMBOTIC THROMBOCYTOPENIC PURPURA 61 11 7.90 2.53 1.33 4.81
RED BLOOD CELL ABNORMALITY 37 5 6.50 3.38 1.33 8.59
HEMIPLEGIC MIGRAINE 33 4 6.32 3.77 1.33 10.63
LAZINESS 33 4 6.32 3.77 1.33 10.63
ATRIAL SEPTAL DEFECT 68 13 8.11 2.39 1.32 4.32
TONGUE ERUPTION 68 13 8.11 2.39 1.32 4.32
CRANIOTOMY 60 11 7.57 2.49 1.31 4.74
ATRIOVENTRICULAR BLOCK FIRST DEGREE 96 21 9.14 2.09 1.30 3.35
LICHEN PLANUS 96 21 9.14 2.09 1.30 3.35
HYDRONEPHROSIS 85 18 8.57 2.16 1.30 3.58
FEMUR FRACTURE 56 10 7.30 2.56 1.30 5.01
DYSPNOEA PAROXYSMAL NOCTURNAL 48 8 6.80 2.74 1.30 5.79
HEART INJURY 28 3 5.79 4.26 1.30 14.01
OVARIAN CYST RUPTURED 28 3 5.79 4.26 1.30 14.01
LAPAROSCOPIC SURGERY 102 23 9.14 2.02 1.29 3.18
ALOPECIA AREATA 92 20 8.85 2.10 1.29 3.41
CARDIAC VALVE DISEASE 40 6 6.33 3.04 1.29 7.18
GALLBLADDER ENLARGEMENT 36 5 6.12 3.29 1.29 8.38
REDUCED FACIAL EXPRESSION 36 5 6.12 3.29 1.29 8.38
ATTENTION DEFICIT HYPERACTIVITY DISORDER 32 4 5.94 3.65 1.29 10.33
EYE COLOUR CHANGE 32 4 5.94 3.65 1.29 10.33
UPPER GASTROINTESTINAL HAEMORRHAGE 66 13 7.46 2.32 1.28 4.20
CHRONIC LYMPHOCYTIC LEUKAEMIA 55 10 6.97 2.51 1.28 4.92
ENDOCARDITIS 55 10 6.97 2.51 1.28 4.92
MANIA 73 15 7.71 2.22 1.27 3.87
COLITIS ISCHAEMIC 62 12 7.18 2.36 1.27 4.38
EFFUSION 62 12 7.18 2.36 1.27 4.38
FEELING OF DESPAIR 62 12 7.18 2.36 1.27 4.38
PNEUMOMEDIASTINUM 43 7 6.20 2.80 1.26 6.23
EPISCLERITIS 39 6 5.97 2.97 1.26 7.01
RESPIRATORY ACIDOSIS 61 12 6.86 2.32 1.25 4.31
STAPHYLOCOCCAL BACTERAEMIA 61 12 6.86 2.32 1.25 4.31
OESOPHAGEAL SPASM 50 9 6.37 2.54 1.25 5.16
INTRACRANIAL MASS 35 5 5.75 3.20 1.25 8.16
ANAL HAEMORRHAGE 31 4 5.56 3.54 1.25 10.02
APTYALISM 31 4 5.56 3.54 1.25 10.02
PULMONARY ARTERIAL HYPERTENSION 27 3 5.40 4.11 1.25 13.54
TONGUE DRY 85 19 7.66 2.04 1.24 3.36
BLOOD GLUCOSE FLUCTUATION 57 11 6.58 2.37 1.24 4.51
LIVER INJURY 57 11 6.58 2.37 1.24 4.51
PERIPHERAL VENOUS DISEASE 74 16 7.08 2.11 1.23 3.62
SICK RELATIVE 53 10 6.30 2.42 1.23 4.76
YAWNING 70 15 6.79 2.13 1.22 3.72
CARDIAC OPERATION 49 9 6.03 2.49 1.22 5.06
COLECTOMY 49 9 6.03 2.49 1.22 5.06
ISCHAEMIC HEPATITIS 49 9 6.03 2.49 1.22 5.06
GENITAL ULCERATION 38 6 5.61 2.89 1.22 6.84
ENTERITIS 45 8 5.77 2.57 1.21 5.45
CAPILLARY FRAGILITY 34 5 5.39 3.10 1.21 7.94
CARDIOPULMONARY FAILURE 34 5 5.39 3.10 1.21 7.94
INTESTINAL PERFORATION 34 5 5.39 3.10 1.21 7.94
B-CELL LYMPHOMA 30 4 5.18 3.42 1.21 9.72
HIDRADENITIS 30 4 5.18 3.42 1.21 9.72
LEG AMPUTATION 30 4 5.18 3.42 1.21 9.72
MUCOSAL HYPERTROPHY 30 4 5.18 3.42 1.21 9.72
NEUTROPHILIA 30 4 5.18 3.42 1.21 9.72
CLOSTRIDIUM DIFFICILE INFECTION 62 13 6.20 2.18 1.20 3.96
BRAIN STEM INFARCTION 41 7 5.51 2.67 1.20 5.96
ELECTROCARDIOGRAM AMBULATORY 41 7 5.51 2.67 1.20 5.96
GENITAL PAIN 41 7 5.51 2.67 1.20 5.96
ABDOMINAL REBOUND TENDERNESS 26 3 5.01 3.96 1.20 13.07
BRAIN STEM STROKE 26 3 5.01 3.96 1.20 13.07
REPETITIVE SPEECH 26 3 5.01 3.96 1.20 13.07
BRAIN DEATH 48 9 5.70 2.43 1.19 4.96
SKIN WRINKLING 48 9 5.70 2.43 1.19 4.96
GINGIVAL DISCOMFORT 51 10 5.66 2.33 1.18 4.59
VITAMIN D DECREASED 44 8 5.43 2.51 1.18 5.33
ENDOMETRIOSIS 40 7 5.17 2.61 1.17 5.82
HAEMOLYSIS 40 7 5.17 2.61 1.17 5.82
OESOPHAGEAL DISORDER 40 7 5.17 2.61 1.17 5.82
FACIAL BONES FRACTURE 67 15 5.90 2.04 1.16 3.57
TONGUE MOVEMENT DISTURBANCE 50 10 5.34 2.28 1.16 4.50
ACNE CYSTIC 29 4 4.81 3.31 1.16 9.41
OESOPHAGEAL PAIN 53 11 5.32 2.20 1.15 4.21
INTERNATIONAL NORMALISED RATIO INCREASED 43 8 5.10 2.45 1.15 5.22
POST VIRAL FATIGUE SYNDROME 36 6 4.91 2.74 1.15 6.50
COR PULMONALE 25 3 4.62 3.80 1.15 12.60
INSULIN-REQUIRING TYPE 2 DIABETES MELLITUS 25 3 4.62 3.80 1.15 12.60
LOGORRHOEA 25 3 4.62 3.80 1.15 12.60
RENAL TRANSPLANT 25 3 4.62 3.80 1.15 12.60
RESPIRATORY TRACT IRRITATION 59 13 5.30 2.07 1.14 3.78
URETERAL STENT INSERTION 32 5 4.67 2.92 1.14 7.50
PLASMA CELL MYELOMA 49 10 5.03 2.24 1.13 4.42
NASAL INJURY 58 13 5.01 2.04 1.12 3.72
FIBROSIS 28 4 4.44 3.20 1.12 9.11
TACHYARRHYTHMIA 48 10 4.72 2.19 1.11 4.33
VENA CAVA FILTER INSERTION 48 10 4.72 2.19 1.11 4.33
GANGRENE 31 5 4.32 2.83 1.10 7.28
VENTRICULAR ARRHYTHMIA 31 5 4.32 2.83 1.10 7.28
ADENOCARCINOMA 24 3 4.24 3.65 1.10 12.13
LOSS OF BLADDER SENSATION 24 3 4.24 3.65 1.10 12.13
LOWER GASTROINTESTINAL HAEMORRHAGE 24 3 4.24 3.65 1.10 12.13
METASTASES TO LIVER 24 3 4.24 3.65 1.10 12.13
COMPLICATION ASSOCIATED WITH DEVICE 44 9 4.43 2.23 1.09 4.57
SUBMAXILLARY GLAND ENLARGEMENT 34 6 4.23 2.59 1.09 6.16
CAPILLARY NAIL REFILL TEST ABNORMAL 47 10 4.42 2.15 1.08 4.25
SINUS ARREST 27 4 4.08 3.08 1.08 8.81
BLOOD GLUCOSE NORMAL 49 11 4.13 2.03 1.06 3.91
LIP HAEMORRHAGE 49 11 4.13 2.03 1.06 3.91
NASAL DISORDER 43 9 4.13 2.18 1.06 4.47
NEPHROTIC SYNDROME 43 9 4.13 2.18 1.06 4.47
ATELECTASIS 725 165 67.25 2.01 1.69 2.37
MENTAL IMPAIRMENT 689 156 64.60 2.02 1.69 2.40
RESPIRATION ABNORMAL 439 99 41.29 2.02 1.63 2.52
EAR INFECTION 375 85 34.79 2.01 1.59 2.55
CARDIAC PACEMAKER INSERTION 238 54 21.81 2.01 1.50 2.70
MOOD SWINGS 186 42 17.10 2.02 1.45 2.83
HAEMODIALYSIS 142 32 12.97 2.03 1.38 2.97
BUNDLE BRANCH BLOCK LEFT 128 29 11.50 2.01 1.35 3.01
SKIN DISCOMFORT 97 22 8.55 2.01 1.27 3.20
SPECIALIST CONSULTATION 79 18 6.79 2.00 1.20 3.34
NORMAL LABOUR 25 3 4.62 3.80 1.15 12.60
ANTINUCLEAR ANTIBODY POSITIVE 35 6 4.57 2.66 1.12 6.33
ABDOMINAL HERNIA 34 6 4.23 2.59 1.09 6.16
DISEASE RECURRENCE 225 2 96.49 51.35 12.76 206.60
CEREBRAL THROMBOSIS 186 1 81.06 84.90 11.90 605.91
COVID-19 IMMUNISATION 191 2 80.98 43.59 10.82 175.57
CEREBRAL VENOUS SINUS THROMBOSIS 150 1 64.64 68.47 9.58 489.26
INTENTIONAL PRODUCT USE ISSUE 141 1 60.53 64.36 9.00 460.09
SARS-COV-2 TEST NEGATIVE 107 1 45.03 48.84 6.82 349.92
HYPERPYREXIA 100 1 41.84 45.65 6.37 327.23
INTENTIONAL DOSE OMISSION 92 1 38.20 42.00 5.85 301.31
RIGHT VENTRICULAR DYSFUNCTION 88 1 36.38 40.17 5.60 288.35
INTRACARDIAC THROMBUS 94 2 36.85 21.45 5.29 87.05
CEREBRAL ARTERY OCCLUSION 93 2 36.39 21.23 5.23 86.14
ABNORMAL UTERINE BLEEDING 82 1 33.65 37.43 5.21 268.91
LYMPHOPENIA 89 2 34.58 20.31 5.00 82.49
CEREBELLAR STROKE 75 1 30.46 34.24 4.76 246.22
SARS-COV-2 ANTIBODY TEST NEGATIVE 71 1 28.64 32.41 4.50 233.26
CEREBRAL MASS EFFECT 70 1 28.19 31.95 4.44 230.02
RIGHT VENTRICULAR DILATATION 67 1 26.83 30.58 4.25 220.30
PERIPHERAL ARTERY THROMBOSIS 75 2 28.25 17.12 4.20 69.71
VACCINATION SITE PARAESTHESIA 73 2 27.34 16.66 4.09 67.89
MYOCARDIAL STRAIN 64 1 25.46 29.21 4.05 210.58
PORTAL VEIN THROMBOSIS 71 2 26.44 16.20 3.97 66.06
INTERNAL HAEMORRHAGE 67 2 24.64 15.29 3.75 62.41
IMPLANTABLE CARDIAC MONITOR INSERTION 58 1 22.74 26.48 3.67 191.14
CHILLBLAINS 65 2 23.74 14.84 3.63 60.59
PRE-EXISTING CONDITION IMPROVED 65 2 23.74 14.84 3.63 60.59
BODY HEIGHT DECREASED 57 1 22.29 26.02 3.60 187.90
TRANSVERSE SINUS THROMBOSIS 55 1 21.38 25.11 3.47 181.42
HAEMOFILTRATION 52 1 20.02 23.74 3.28 171.70
CRITICAL ILLNESS 58 2 20.59 13.24 3.23 54.20
MESENTERIC VEIN THROMBOSIS 51 1 19.57 23.28 3.22 168.46
CORONARY ARTERY DISSECTION 50 1 19.12 22.82 3.15 165.22
JUGULAR VEIN THROMBOSIS 49 1 18.66 22.37 3.09 161.98
NIH STROKE SCALE 48 1 18.21 21.91 3.02 158.74
NIH STROKE SCALE ABNORMAL 47 1 17.76 21.45 2.96 155.50
NEUROLOGIC NEGLECT SYNDROME 46 1 17.31 21.00 2.90 152.26
COOLING THERAPY 52 2 17.91 11.87 2.89 48.72
LEFT VENTRICULAR DILATATION 45 1 16.86 20.54 2.83 149.02
PLATELET COUNT INCREASED 45 1 16.86 20.54 2.83 149.02
THROMBOEMBOLECTOMY 45 1 16.86 20.54 2.83 149.02
DEPERSONALISATION/DEREALISATION DISORDER 44 1 16.40 20.08 2.77 145.78
PREMENSTRUAL PAIN 44 1 16.40 20.08 2.77 145.78
PRODUCT RECONSTITUTION QUALITY ISSUE 44 1 16.40 20.08 2.77 145.78
COR PULMONALE ACUTE 42 1 15.50 19.17 2.64 139.30
HEPATIC MASS 42 1 15.50 19.17 2.64 139.30
TOTAL LUNG CAPACITY DECREASED 41 1 15.05 18.72 2.57 136.06
SENSATION OF BLOOD FLOW 46 2 15.23 10.50 2.55 43.25
PERIPHERAL ARTERY OCCLUSION 40 1 14.60 18.26 2.51 132.81
AORTIC DISSECTION 44 2 14.35 10.04 2.43 41.42
CARDIAC FAILURE CHRONIC 44 2 14.35 10.04 2.43 41.42
MYOCARDIAL FIBROSIS 43 2 13.90 9.81 2.38 40.51
FREEZING PHENOMENON 38 1 13.70 17.35 2.38 126.33
LUNG ASSIST DEVICE THERAPY 42 2 13.46 9.59 2.32 39.60
ACUTE CARDIAC EVENT 37 1 13.25 16.89 2.32 123.10
SENSITISATION 37 1 13.25 16.89 2.32 123.10
BRAIN OPERATION 41 2 13.02 9.36 2.26 38.69
SUBDURAL HAEMORRHAGE 41 2 13.02 9.36 2.26 38.69
CARDIOVASCULAR SYMPTOM 36 1 12.80 16.43 2.25 119.86
FEELING OF RELAXATION 36 1 12.80 16.43 2.25 119.86
GLYCOSYLATED HAEMOGLOBIN INCREASED 40 2 12.58 9.13 2.21 37.77
NIH STROKE SCALE SCORE INCREASED 40 2 12.58 9.13 2.21 37.77
RED BLOOD CELL COUNT DECREASED 40 2 12.58 9.13 2.21 37.77
PRODUCT ADMINISTRATION INTERRUPTED 34 1 11.91 15.52 2.12 113.38
ARTERIAL CATHETERISATION 38 2 11.70 8.67 2.09 35.95
VESTIBULAR MIGRAINE 38 2 11.70 8.67 2.09 35.95
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 33 1 11.46 15.06 2.06 110.14
LACUNAR STROKE 33 1 11.46 15.06 2.06 110.14
PLEURAL THICKENING 33 1 11.46 15.06 2.06 110.14
VITAL FUNCTIONS ABNORMAL 33 1 11.46 15.06 2.06 110.14
PARANASAL SINUS INFLAMMATION 37 2 11.27 8.44 2.04 35.04
CEREBRAL ARTERY STENOSIS 36 2 10.83 8.22 1.98 34.12
CHILD MALTREATMENT SYNDROME 31 1 10.56 14.15 1.93 103.66
LACK OF SPONTANEOUS SPEECH 31 1 10.56 14.15 1.93 103.66
MITRAL VALVE CALCIFICATION 31 1 10.56 14.15 1.93 103.66
AORTIC VALVE REPLACEMENT 35 2 10.39 7.99 1.92 33.21
RESPIRATORY SYNCYTIAL VIRUS INFECTION 35 2 10.39 7.99 1.92 33.21
ARTERIAL THROMBOSIS 30 1 10.12 13.69 1.87 100.42
RETINAL MIGRAINE 34 2 9.96 7.76 1.86 32.30
OVERSENSING 33 2 9.52 7.53 1.81 31.39
COLON CANCER 29 1 9.67 13.24 1.80 97.18
CYTOKINE STORM 29 1 9.67 13.24 1.80 97.18
EYELID SENSORY DISORDER 29 1 9.67 13.24 1.80 97.18
INTRA-ABDOMINAL FLUID COLLECTION 29 1 9.67 13.24 1.80 97.18
METASTASES TO BONE 29 1 9.67 13.24 1.80 97.18
ENDOMETRIAL THICKENING 32 2 9.09 7.30 1.75 30.48
INJECTION 32 2 9.09 7.30 1.75 30.48
VACCINATION SITE SCAR 32 2 9.09 7.30 1.75 30.48
CEREBRAL ARTERY EMBOLISM 28 1 9.23 12.78 1.74 93.94
DIURETIC THERAPY 28 1 9.23 12.78 1.74 93.94
URINARY TRACT DISCOMFORT 28 1 9.23 12.78 1.74 93.94
IDIOPATHIC INTRACRANIAL HYPERTENSION 31 2 8.66 7.08 1.69 29.56
THYROID PAIN 31 2 8.66 7.08 1.69 29.56
DAYDREAMING 27 1 8.79 12.32 1.67 90.70
PRODUCT DOSE OMISSION IN ERROR 27 1 8.79 12.32 1.67 90.70
BEHAVIOUR DISORDER 30 2 8.23 6.85 1.64 28.65
PRODUCT AVAILABILITY ISSUE 30 2 8.23 6.85 1.64 28.65
HAEMORRHAGIC TRANSFORMATION STROKE 26 1 8.34 11.87 1.61 87.46
INJECTION RELATED REACTION 26 1 8.34 11.87 1.61 87.46
OVULATION DISORDER 26 1 8.34 11.87 1.61 87.46
PARAESTHESIA EAR 26 1 8.34 11.87 1.61 87.46
RIGHT ATRIAL ENLARGEMENT 26 1 8.34 11.87 1.61 87.46
COLD-STIMULUS HEADACHE 29 2 7.81 6.62 1.58 27.74
HYPERVIGILANCE 29 2 7.81 6.62 1.58 27.74
SUBCLAVIAN VEIN THROMBOSIS 29 2 7.81 6.62 1.58 27.74
VASCULAR DEMENTIA 25 1 7.90 11.41 1.55 84.22
DYSHIDROTIC ECZEMA 28 2 7.38 6.39 1.52 26.83
LEFT VENTRICULAR ENLARGEMENT 24 1 7.46 10.96 1.48 80.98
MENSTRUATION NORMAL 24 1 7.46 10.96 1.48 80.98
SEDATIVE THERAPY 24 1 7.46 10.96 1.48 80.98
MULTIMORBIDITY 27 2 6.96 6.16 1.47 25.91
PULMONARY VASCULAR DISORDER 27 2 6.96 6.16 1.47 25.91
VASOGENIC CEREBRAL OEDEMA 27 2 6.96 6.16 1.47 25.91
BASAL GANGLIA HAEMORRHAGE 23 1 7.02 10.50 1.42 77.74
BREAST DISORDER FEMALE 23 1 7.02 10.50 1.42 77.74
EAR INFLAMMATION 23 1 7.02 10.50 1.42 77.74
INFERIOR VENA CAVA DILATATION 23 1 7.02 10.50 1.42 77.74
VEIN RUPTURE 23 1 7.02 10.50 1.42 77.74
ANTIINFLAMMATORY THERAPY 26 2 6.54 5.93 1.41 25.00
AORTIC THROMBOSIS 26 2 6.54 5.93 1.41 25.00
THORACIC CAVITY DRAINAGE 26 2 6.54 5.93 1.41 25.00
FOOD CRAVING 25 2 6.12 5.71 1.35 24.09
HAND DERMATITIS 25 2 6.12 5.71 1.35 24.09
PRODUCT DISPENSING ISSUE 22 1 6.58 10.04 1.35 74.50
ANEMBRYONIC GESTATION 24 2 5.70 5.48 1.29 23.18
PANCREATIC CYST 24 2 5.70 5.48 1.29 23.18
PULMONARY CALCIFICATION 24 2 5.70 5.48 1.29 23.18
DENTAL PARAESTHESIA 21 1 6.15 9.59 1.29 71.26
ORBITAL SWELLING 21 1 6.15 9.59 1.29 71.26
PLATELET DISORDER 21 1 6.15 9.59 1.29 71.26
SUPERFICIAL VEIN PROMINENCE 21 1 6.15 9.59 1.29 71.26
ORGANISING PNEUMONIA 23 2 5.29 5.25 1.24 22.26
PATHOGEN RESISTANCE 23 2 5.29 5.25 1.24 22.26
PNEUMOPERITONEUM 23 2 5.29 5.25 1.24 22.26
THROMBOSIS PROPHYLAXIS 23 2 5.29 5.25 1.24 22.26
BLUE TOE SYNDROME 20 1 5.71 9.13 1.23 68.02
CHEYNE-STOKES RESPIRATION 20 1 5.71 9.13 1.23 68.02
FEMORAL NECK FRACTURE 20 1 5.71 9.13 1.23 68.02
LARGE INTESTINE PERFORATION 20 1 5.71 9.13 1.23 68.02
LOSS OF LIBIDO 20 1 5.71 9.13 1.23 68.02
OXYGEN CONSUMPTION DECREASED 20 1 5.71 9.13 1.23 68.02
PULMONARY ARTERY DILATATION 20 1 5.71 9.13 1.23 68.02
SPLENIC VEIN THROMBOSIS 20 1 5.71 9.13 1.23 68.02
AORTIC DISORDER 22 2 4.88 5.02 1.18 21.35
CHOLECYSTITIS INFECTIVE 22 2 4.88 5.02 1.18 21.35
CORNEAL LIGHT REFLEX TEST ABNORMAL 22 2 4.88 5.02 1.18 21.35
VENTRICULAR DRAINAGE 22 2 4.88 5.02 1.18 21.35
FASTING 19 1 5.28 8.67 1.16 64.79
METASTASES TO LYMPH NODES 19 1 5.28 8.67 1.16 64.79
MONOCLONAL ANTIBODY UNCONJUGATED THERAPY 19 1 5.28 8.67 1.16 64.79
NEUTROPHIL COUNT INCREASED 19 1 5.28 8.67 1.16 64.79
METASTASES TO CENTRAL NERVOUS SYSTEM 21 2 4.48 4.79 1.12 20.44
VERTEBRAL ARTERY OCCLUSION 21 2 4.48 4.79 1.12 20.44
ARTERIAL STENT INSERTION 18 1 4.85 8.22 1.10 61.55
CEREBRAL HAEMATOMA 18 1 4.85 8.22 1.10 61.55
DECEREBRATE POSTURE 18 1 4.85 8.22 1.10 61.55
GASTRIC HAEMORRHAGE 18 1 4.85 8.22 1.10 61.55
HAEMOPERITONEUM 18 1 4.85 8.22 1.10 61.55
OXYGEN CONSUMPTION INCREASED 18 1 4.85 8.22 1.10 61.55
VACCINATION SITE COLDNESS 18 1 4.85 8.22 1.10 61.55
VENTRICULAR ASSIST DEVICE INSERTION 18 1 4.85 8.22 1.10 61.55
ANOVULATORY CYCLE 20 2 4.08 4.56 1.07 19.53
BLOOD THYROID STIMULATING HORMONE DECREASED 20 2 4.08 4.56 1.07 19.53
CHOLANGITIS 20 2 4.08 4.56 1.07 19.53
MITRAL VALVE STENOSIS 20 2 4.08 4.56 1.07 19.53
NEUTROPHIL COUNT DECREASED 20 2 4.08 4.56 1.07 19.53
SACRAL PAIN 20 2 4.08 4.56 1.07 19.53
THUNDERCLAP HEADACHE 20 2 4.08 4.56 1.07 19.53
ABDOMINAL WALL HAEMATOMA 17 1 4.43 7.76 1.03 58.31
EMBOLIC CEREBRAL INFARCTION 17 1 4.43 7.76 1.03 58.31
ENDOMETRIAL ABLATION 17 1 4.43 7.76 1.03 58.31
EPSTEIN-BARR VIRUS INFECTION REACTIVATION 17 1 4.43 7.76 1.03 58.31
RED BLOOD CELL COUNT INCREASED 17 1 4.43 7.76 1.03 58.31
RENAL STONE REMOVAL 17 1 4.43 7.76 1.03 58.31
SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 17 1 4.43 7.76 1.03 58.31
TERMINAL INSOMNIA 17 1 4.43 7.76 1.03 58.31
BREAST CANCER METASTATIC 16 1 4.01 7.30 0.97 55.07
CARDIAC ANEURYSM 16 1 4.01 7.30 0.97 55.07
GALACTOSTASIS 16 1 4.01 7.30 0.97 55.07
HAEMORRHOIDS THROMBOSED 16 1 4.01 7.30 0.97 55.07
INFECTIOUS PLEURAL EFFUSION 16 1 4.01 7.30 0.97 55.07
INTRUSIVE THOUGHTS 16 1 4.01 7.30 0.97 55.07
POSITIVE END-EXPIRATORY PRESSURE 16 1 4.01 7.30 0.97 55.07
SINONASAL OBSTRUCTION 16 1 4.01 7.30 0.97 55.07
UTERINE POLYP 16 1 4.01 7.30 0.97 55.07
VASCULAR PSEUDOANEURYSM 16 1 4.01 7.30 0.97 55.07
VOLVULUS 16 1 4.01 7.30 0.97 55.07
BLOOD LACTIC ACID INCREASED 20 2 4.08 4.56 1.07 19.53
VERTEBRAL ARTERY STENOSIS 20 2 4.08 4.56 1.07 19.53
CAPILLARY DISORDER 16 1 4.01 7.30 0.97 55.07
DEFAECATION DISORDER 16 1 4.01 7.30 0.97 55.07
DISTRIBUTIVE SHOCK 16 1 4.01 7.30 0.97 55.07
FOLLICULAR LYMPHOMA 16 1 4.01 7.30 0.97 55.07
THERAPEUTIC PRODUCT EFFECT DECREASED 16 1 4.01 7.30 0.97 55.07
TOE AMPUTATION 16 1 4.01 7.30 0.97 55.07
URINARY BLADDER HAEMORRHAGE 16 1 4.01 7.30 0.97 55.07
WRONG PATIENT 47 1 17.76 21.45 2.96 155.50
PAIN ASSESSMENT 12 1 2.37 5.48 0.71 42.13
PROCTITIS ULCERATIVE 6 1 0.32 2.74 0.33 22.75
  • PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
  • For Current Week and Past Week Comparison
  • Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
  • Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
  • SERIOUS AGES 5 YEARS-11 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
  • Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
  • N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
  • MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
  • SERIOUS AGES 5 YEARS-11 YEARS excludes missing ages
MedDRA Codes ALL Reports (SERIOUS AGES 5 YEARS-11 YEARS) 12/14/2020-03/18/2022 COVID19 mRNA N=228 01/01/2009-03/18/2022 NON-COVID19 N=1885 12/14-03/18 Chi-Square 12/14-03/18 PRR 12/14-03/18 LCL 12/14-03/18 UCL
APPENDICITIS 12 3 68.11 33.07 9.40 116.31
MYOCARDITIS 10 4 47.68 20.67 6.54 65.36
CONJUNCTIVITIS 16 10 65.19 13.23 6.08 28.80
KAWASAKI'S DISEASE 7 3 30.67 19.29 5.02 74.08
APPENDICECTOMY 8 8 21.81 8.27 3.13 21.82
CHEST PAIN 25 48 40.73 4.31 2.71 6.84
SHOCK 6 6 15.40 8.27 2.69 25.42
HYPOTENSION 14 25 23.43 4.63 2.44 8.78
CONJUNCTIVAL HYPERAEMIA 6 8 11.89 6.20 2.17 17.71
ABDOMINAL PAIN LOWER 4 4 9.06 8.27 2.08 32.83
SEIZURE 22 60 21.10 3.03 1.90 4.84
ERYTHEMA MULTIFORME 3 3 5.96 8.27 1.68 40.72
GASTROINTESTINAL DISORDER 3 3 5.96 8.27 1.68 40.72
PANIC ATTACK 3 3 5.96 8.27 1.68 40.72
CONDITION AGGRAVATED 21 67 14.92 2.59 1.62 4.15
INFLAMMATION 7 15 8.12 3.86 1.59 9.36
NEPHROTIC SYNDROME 3 4 4.53 6.20 1.40 27.53
PAINFUL RESPIRATION 3 4 4.53 6.20 1.40 27.53
ACUTE RESPIRATORY FAILURE 4 7 5.08 4.72 1.39 16.01
HEART RATE INCREASED 7 20 5.01 2.89 1.24 6.77
HYPOXIA 7 22 4.13 2.63 1.14 6.09
CHAPPED LIPS 4 5 7.41 6.61 1.79 24.45
RASH 32 128 14.24 2.07 1.44 2.97
HYPONATRAEMIA 4 8 4.23 4.13 1.25 13.62
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN 33 1 258.13 272.83 37.49 1985.31
COVID-19 29 1 224.19 239.76 32.82 1751.73
LEFT VENTRICULAR DYSFUNCTION 8 1 49.41 66.14 8.31 526.41
ILLNESS 5 1 25.77 41.34 4.85 352.27
PERICARDIAL EFFUSION 5 1 25.77 41.34 4.85 352.27
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 4 1 18.25 33.07 3.71 294.60
PERICARDITIS 4 1 18.25 33.07 3.71 294.60
TRICUSPID VALVE INCOMPETENCE 3 1 11.13 24.80 2.59 237.45
HEPATOMEGALY 3 2 8.00 12.40 2.08 73.83
PLEURAL EFFUSION 3 2 8.00 12.40 2.08 73.83
VENTRICULAR EXTRASYSTOLES 3 2 8.00 12.40 2.08 73.83
  • PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
  • For Current Week and Past Week Comparison
  • Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
  • Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
  • SERIOUS AGES 12 YEARS-17 YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
  • Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
  • N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
  • MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
  • SERIOUS AGES 12 YEARS-17 YEARS excludes missing ages
MedDRA Codes ALL Reports (SERIOUS 12 Yrs-17 Yrs) 12/14/2020-03/18/2022 COVID19 mRNA N=1772 01/01/2009-03/18/2022 NON-COVID19 N=2387 12/14-03/18 Chi-Square 12/14-03/18 PRR 12/14-03/18 LCL 12/14-03/18 UCL
MYOCARDITIS 636 12 965.66 71.39 40.46 125.97
RESPIRATORY RATE INCREASED 143 6 177.73 32.11 14.22 72.49
PERICARDITIS 143 9 168.76 21.40 10.94 41.86
BLOOD PRESSURE INCREASED 122 14 125.56 11.74 6.78 20.34
PAINFUL RESPIRATION 84 9 86.59 12.57 6.34 24.93
ANTICOAGULANT THERAPY 51 4 55.20 17.18 6.22 47.43
CHEST PAIN 873 168 964.21 7.00 6.01 8.16
PERICARDIAL EFFUSION 60 7 59.44 11.55 5.29 25.20
RESPIRATORY RATE DECREASED 38 3 40.42 17.06 5.28 55.19
HEART RATE DECREASED 57 7 55.45 10.97 5.02 23.99
PLEURITIC PAIN 33 3 33.75 14.82 4.55 48.24
CHEST DISCOMFORT 250 61 194.53 5.52 4.20 7.25
HEART RATE INCREASED 177 52 117.74 4.59 3.39 6.21
SINUS ARRHYTHMIA 24 3 21.94 10.78 3.25 35.73
APPENDICITIS 51 12 36.89 5.73 3.06 10.70
BLOOD PRESSURE DECREASED 76 21 50.41 4.88 3.02 7.87
BODY TEMPERATURE INCREASED 77 24 46.48 4.32 2.74 6.81
PULMONARY EMBOLISM 25 5 18.85 6.74 2.58 17.56
TACHYPNOEA 60 20 33.67 4.04 2.45 6.68
INTENSIVE CARE 339 157 151.40 2.91 2.43 3.48
ACUTE KIDNEY INJURY 29 8 18.09 4.88 2.24 10.66
SINUS TACHYCARDIA 39 14 19.80 3.75 2.04 6.89
OXYGEN SATURATION DECREASED 48 19 22.29 3.40 2.01 5.77
MUSCULOSKELETAL CHEST PAIN 37 14 17.71 3.56 1.93 6.56
DECREASED ACTIVITY 45 19 19.27 3.19 1.87 5.43
LYMPHOPENIA 14 3 9.46 6.29 1.81 21.84
DYSPNOEA 384 250 97.82 2.07 1.79 2.40
SINUS BRADYCARDIA 19 6 10.14 4.27 1.71 10.66
TACHYCARDIA 203 131 48.24 2.09 1.69 2.58
BREATH SOUNDS ABNORMAL 32 14 12.73 3.08 1.65 5.75
PALPITATIONS 122 76 29.91 2.16 1.63 2.86
VACCINATION COMPLICATION 133 85 31.07 2.11 1.62 2.75
APPENDICECTOMY 42 22 13.14 2.57 1.54 4.29
LIMB DISCOMFORT 31 15 10.68 2.78 1.51 5.14
ACUTE RESPIRATORY FAILURE 21 9 8.18 3.14 1.44 6.85
HEAVY MENSTRUAL BLEEDING 13 4 6.68 4.38 1.43 13.40
ELECTROCARDIOGRAM AMBULATORY 11 3 6.03 4.94 1.38 17.68
OROPHARYNGEAL DISCOMFORT 11 3 6.03 4.94 1.38 17.68
ABDOMINAL PAIN LOWER 35 20 9.23 2.36 1.37 4.07
STEROID THERAPY 17 7 6.75 3.27 1.36 7.87
THROMBOSIS 15 6 6.03 3.37 1.31 8.66
TRANSAMINASES INCREASED 15 6 6.03 3.37 1.31 8.66
PLEURAL EFFUSION 24 13 6.67 2.49 1.27 4.87
DYSPNOEA EXERTIONAL 30 19 6.28 2.13 1.20 3.77
PAIN IN JAW 24 14 5.80 2.31 1.20 4.45
INFLAMMATION 30 20 5.56 2.02 1.15 3.55
CARDIAC ARREST 22 13 5.11 2.28 1.15 4.51
IMMUNE THROMBOCYTOPENIA 12 5 4.38 3.23 1.14 9.16
HYPOXIA 27 18 4.93 2.02 1.12 3.66
CONJUNCTIVITIS 19 11 4.49 2.33 1.11 4.88
CARDIOMEGALY 13 6 4.20 2.92 1.11 7.66
ELECTROCARDIOGRAM QT PROLONGED 10 3 4.95 4.49 1.24 16.29
BRADYCARDIA 39 26 7.46 2.02 1.23 3.31
TROPONIN INCREASED 121 1 162.13 162.99 22.80 1165.38
ELECTROCARDIOGRAM ST SEGMENT ELEVATION 111 1 147.90 149.52 20.90 1069.85
COVID-19 94 2 120.63 63.31 15.62 256.54
MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN 52 1 65.36 70.05 9.69 506.20
VENTRICULAR TACHYCARDIA 39 2 44.56 26.27 6.35 108.64
TROPONIN I INCREASED 33 1 39.35 44.45 6.09 324.71
MITRAL VALVE INCOMPETENCE 31 1 36.63 41.76 5.71 305.60
VENTRICULAR EXTRASYSTOLES 28 1 32.57 37.72 5.14 276.95
EPINEPHRINE 22 1 24.48 29.64 4.00 219.65
TRICUSPID VALVE INCOMPETENCE 22 1 24.48 29.64 4.00 219.65
BLOOD PRESSURE DIASTOLIC INCREASED 18 1 19.12 24.25 3.24 181.46
ILLNESS 16 1 16.47 21.55 2.86 162.37
ELECTROCARDIOGRAM T WAVE INVERSION 14 2 11.46 9.43 2.15 41.44
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 14 2 11.46 9.43 2.15 41.44
HEART SOUNDS ABNORMAL 13 2 10.21 8.76 1.98 38.75
EXPOSURE TO SARS-COV-2 10 1 8.64 13.47 1.73 105.13
SEDATION 10 1 8.64 13.47 1.73 105.13
APPENDICITIS PERFORATED 9 1 7.37 12.12 1.54 95.60
PHARYNGEAL SWELLING 9 1 7.37 12.12 1.54 95.60
BLOOD PRESSURE SYSTOLIC DECREASED 10 2 6.58 6.74 1.48 30.70
ISCHAEMIC STROKE 10 2 6.58 6.74 1.48 30.70
C-REACTIVE PROTEIN INCREASED 8 1 6.12 10.78 1.35 86.08
PULMONARY VALVE INCOMPETENCE 8 1 6.12 10.78 1.35 86.08
BUNDLE BRANCH BLOCK RIGHT 7 1 4.89 9.43 1.16 76.57
ANGINA PECTORIS 8 2 4.30 5.39 1.15 25.34
LYMPH NODE PAIN 8 2 4.30 5.39 1.15 25.34
  • PREFERRED Medical Dictionary for Regulatory Activities (MedDRA) Terms (VAERS-1 Box 7, VAERS 2.0 Box 18)
  • For Current Week and Past Week Comparison
  • Following ALL 12/14/2020-03/18/2022 COVID19 mRNA Vaccines (Pfizer Ages 5+ & Moderna Ages 18+)
  • Compared to ALL 01/01/2009-03/18/2022 NON-COVID19 Vaccines
  • SERIOUS AGES 18+ YEARS, Initial domestic reports only, VAERS reports as of 03/18/2022
  • Vaccination, Received, and Completed Date: 12/14 - 03/18 (Current Week) and 12/14 - 03/11 (Past Week)
  • N>=3 (Current Week), PRR>=2.00 (Ratio of Proportions), Chi-Square>=4.00
  • MedDRA PTs sorting based on lower confidence limit and COVID19 mRNA adverse event count from 12/14/2020-03/18/2022
  • SERIOUS AGES 18+ YEARS YEARS excludes missing ages
MedDRA Codes ALL Reports (18+) 12/14/2020-03/18/2022 COVID19 mRNA N=64385 01/01/2009-03/18/2022 NON-COVID19 N=15797 12/14-03/18 Chi-Square 12/14-03/18 PRR 12/14-03/18 LCL 12/14-03/18 UCL
COVID-19 16654 40 5046.30 102.15 74.94 139.25
COVID-19 PNEUMONIA 3901 7 988.42 136.73 65.15 286.94
LUNG OPACITY 1535 7 366.94 53.80 25.61 113.02
PULMONARY THROMBOSIS 524 3 121.53 42.85 13.78 133.29
POSITIVE AIRWAY PRESSURE THERAPY 648 6 145.87 26.50 11.86 59.19
ANTICOAGULANT THERAPY 3043 57 649.22 13.10 10.08 17.01
INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 878 20 174.18 10.77 6.92 16.77
THROMBECTOMY 312 5 64.94 15.31 6.33 37.03
ILLNESS 459 10 90.94 11.26 6.02 21.07
APPENDICITIS 519 16 94.01 7.96 4.84 13.08
PULMONARY EMBOLISM 2578 116 416.66 5.45 4.53 6.56
THROMBOSIS 1305 60 204.65 5.34 4.12 6.91
EPINEPHRINE 285 9 50.60 7.77 4.00 15.08
UNEVALUABLE EVENT 2049 106 304.94 4.74 3.90 5.76
LEFT VENTRICULAR FAILURE 193 6 34.06 7.89 3.50 17.78
BELL'S PALSY 441 21 66.51 5.15 3.33 7.98
ANOSMIA 355 16 54.82 5.44 3.30 8.98
DEATH 8428 608 1082.41 3.40 3.14 3.69
STENT PLACEMENT 245 11 37.55 5.46 2.99 10.00
RESPIRATORY RATE INCREASED 1010 65 127.55 3.81 2.97 4.90
HYPERVOLAEMIA 177 7 28.46 6.20 2.92 13.20
PULMONARY INFARCTION 111 3 19.96 9.08 2.88 28.57
CARDIAC FAILURE ACUTE 260 13 37.70 4.91 2.81 8.56
GENERAL PHYSICAL CONDITION ABNORMAL 229 11 33.83 5.11 2.79 9.35
APPENDICECTOMY 405 24 53.36 4.14 2.74 6.25
BLOOD LOSS ANAEMIA 134 5 21.82 6.58 2.69 16.05
BLOOD PRESSURE SYSTOLIC INCREASED 393 24 50.65 4.02 2.66 6.06
RESPIRATORY RATE DECREASED 217 11 31.05 4.84 2.64 8.87
END STAGE RENAL DISEASE 143 6 22.20 5.85 2.58 13.23
ISCHAEMIC STROKE 438 30 51.72 3.58 2.48 5.18
IMMUNE THROMBOCYTOPENIA 268 16 34.77 4.11 2.48 6.80
ACUTE RESPIRATORY FAILURE 3159 286 294.93 2.71 2.40 3.05
HEART RATE DECREASED 619 48 65.69 3.16 2.36 4.24
ACUTE LEFT VENTRICULAR FAILURE 117 5 17.83 5.74 2.35 14.05
OXYGEN SATURATION DECREASED 2123 193 194.08 2.70 2.33 3.12
ACUTE MYOCARDIAL INFARCTION 1254 110 118.03 2.80 2.30 3.40
TROPONIN INCREASED 334 24 37.58 3.41 2.26 5.16
CORONARY ARTERIAL STENT INSERTION 233 15 28.45 3.81 2.26 6.42
IMMUNISATION 138 7 19.38 4.84 2.26 10.33
DEEP VEIN THROMBOSIS 1315 119 119.28 2.71 2.25 3.27
CEREBROVASCULAR ACCIDENT 2494 242 210.33 2.53 2.22 2.88
HOSPICE CARE 214 14 25.73 3.75 2.18 6.44
GENERAL PHYSICAL HEALTH DETERIORATION 807 73 72.44 2.71 2.14 3.44
CHRONIC KIDNEY DISEASE 496 42 47.69 2.90 2.12 3.97
SUPERINFECTION 82 3 13.06 6.71 2.12 21.22
DRUG INEFFECTIVE 129 7 17.33 4.52 2.11 9.67
GENERAL SYMPTOM 105 5 15.05 5.15 2.10 12.63
VENTRICULAR HYPOKINESIA 137 8 17.59 4.20 2.06 8.57
CARDIAC FAILURE 535 48 48.09 2.73 2.04 3.67
CORONARY ARTERY OCCLUSION 176 12 20.29 3.60 2.01 6.46
HYPOXIA 3280 361 230.27 2.23 2.00 2.48
CHRONIC LEFT VENTRICULAR FAILURE 122 7 15.75 4.28 2.00 9.16
LUNG INFILTRATION 968 99 73.60 2.40 1.95 2.95
PHARYNGEAL SWELLING 392 35 35.19 2.75 1.95 3.88
CEREBRAL INFARCTION 381 34 34.20 2.75 1.94 3.90
DEMENTIA 341 30 31.05 2.79 1.92 4.05
LUNG CONSOLIDATION 292 25 27.34 2.87 1.91 4.31
INFUSION 106 6 13.69 4.33 1.90 9.86
AUTOPSY 317 28 28.67 2.78 1.89 4.09
MULTIPLE ORGAN DYSFUNCTION SYNDROME 241 20 23.23 2.96 1.87 4.66
MYOCARDIAL INFARCTION 1227 136 82.24 2.21 1.86 2.64
PNEUMONIA BACTERIAL 283 25 25.50 2.78 1.85 4.18
AGEUSIA 461 46 35.76 2.46 1.82 3.33
HOSPITALISATION 111 7 13.30 3.89 1.81 8.35
PULSELESS ELECTRICAL ACTIVITY 293 27 25.06 2.66 1.80 3.95
CARDIAC ARREST 1432 170 84.79 2.07 1.76 2.42
CARDIO-RESPIRATORY ARREST 574 63 38.45 2.24 1.72 2.90
EMBOLIC STROKE 86 5 10.74 4.22 1.71 10.39
PULSE ABSENT 574 64 37.40 2.20 1.70 2.85
ELECTROCARDIOGRAM ST SEGMENT ELEVATION 211 19 18.37 2.72 1.70 4.36
ELECTRIC SHOCK SENSATION 113 8 12.31 3.47 1.69 7.10
APPENDICITIS PERFORATED 103 7 11.56 3.61 1.68 7.76
PNEUMONIA VIRAL 138 11 13.55 3.08 1.67 5.69
CEREBRAL HAEMORRHAGE 370 40 25.14 2.27 1.64 3.14
HYPERTENSIVE EMERGENCY 73 4 9.36 4.48 1.64 12.25
ATYPICAL PNEUMONIA 90 6 10.16 3.68 1.61 8.41
CARDIOGENIC SHOCK 228 23 17.01 2.43 1.58 3.73
RETINAL ARTERY OCCLUSION 79 5 9.20 3.88 1.57 9.57
BLOOD PRESSURE DIASTOLIC DECREASED 96 7 10.06 3.36 1.56 7.25
EXTRA DOSE ADMINISTERED 177 17 14.02 2.55 1.55 4.20
BLOOD PRESSURE SYSTOLIC DECREASED 68 4 8.24 4.17 1.52 11.43
TASTE DISORDER 163 16 12.46 2.50 1.50 4.18
RESPIRATORY SYMPTOM 185 19 13.30 2.39 1.49 3.83
DRAINAGE 58 3 7.52 4.74 1.49 15.14
DEMENTIA ALZHEIMER'S TYPE 105 9 9.33 2.86 1.45 5.65
EJECTION FRACTION DECREASED 179 19 12.18 2.31 1.44 3.71
CORONARY ARTERY THROMBOSIS 56 3 7.08 4.58 1.43 14.63
OROPHARYNGEAL DISCOMFORT 109 10 8.91 2.67 1.40 5.11
ATRIOVENTRICULAR BLOCK COMPLETE 77 6 7.40 3.15 1.37 7.22
CARDIAC FLUTTER 135 14 9.38 2.37 1.36 4.10
SUDDEN DEATH 158 18 9.42 2.15 1.32 3.51
HEPATIC CIRRHOSIS 122 13 8.05 2.30 1.30 4.08
GASTROINTESTINAL WALL THICKENING 51 3 5.97 4.17 1.30 13.36
PALLIATIVE CARE 79 7 6.56 2.77 1.28 6.00
ANGINA UNSTABLE 50 3 5.75 4.09 1.28 13.11
THALAMIC INFARCTION 57 4 5.86 3.50 1.27 9.63
AORTIC ANEURYSM 90 9 6.40 2.45 1.24 4.87
IMPAIRED SELF-CARE 70 6 5.98 2.86 1.24 6.59
HAEMORRHAGIC STROKE 109 12 6.73 2.23 1.23 4.04
PULSE ABNORMAL 108 12 6.55 2.21 1.22 4.01
THROMBOLYSIS 55 4 5.44 3.37 1.22 9.31
LYMPHADENOPATHY MEDIASTINAL 94 10 6.07 2.31 1.20 4.43
PERICARDIAL DRAINAGE 86 9 5.66 2.34 1.18 4.66
JUGULAR VEIN DISTENSION 53 4 5.03 3.25 1.18 8.98
CARDIAC ABLATION 104 12 5.85 2.13 1.17 3.86
CHOLECYSTITIS ACUTE 46 3 4.89 3.76 1.17 12.09
HILAR LYMPHADENOPATHY 52 4 4.82 3.19 1.15 8.82
IMPLANTABLE DEFIBRILLATOR INSERTION 76 8 4.88 2.33 1.13 4.83
ACUTE CORONARY SYNDROME 70 7 4.83 2.45 1.13 5.33
ACQUIRED DIAPHRAGMATIC EVENTRATION 44 3 4.46 3.60 1.12 11.59
RETINAL VEIN OCCLUSION 44 3 4.46 3.60 1.12 11.59
SUDDEN CARDIAC DEATH 61 6 4.24 2.49 1.08 5.77
HEPATIC LESION 49 4 4.21 3.01 1.08 8.33
PERIPHERAL ISCHAEMIA 49 4 4.21 3.01 1.08 8.33
SYSTOLIC DYSFUNCTION 49 4 4.21 3.01 1.08 8.33
ELECTROCARDIOGRAM ST SEGMENT DEPRESSION 42 3 4.05 3.43 1.06 11.08
ARTERIAL OCCLUSIVE DISEASE 61 6 4.24 2.49 1.08 5.77
VACCINE BREAKTHROUGH INFECTION 2580 2 648.16 316.50 79.12 1266.06
EXPOSURE TO SARS-COV-2 662 1 160.28 162.42 22.85 1154.67
ASYMPTOMATIC COVID-19 492 2 115.77 60.36 15.05 241.99
BLOOD PRESSURE DIASTOLIC INCREASED 173 2 37.02 21.22 5.27 85.53
CEREBRAL VENOUS SINUS THROMBOSIS 143 1 31.75 35.09 4.91 250.76
SUSPECTED COVID-19 130 1 28.56 31.90 4.46 228.12
OFF LABEL USE 95 1 19.99 23.31 3.25 167.17
RIGHT VENTRICULAR DYSFUNCTION 83 1 17.06 20.36 2.84 146.27
CEREBRAL ARTERY OCCLUSION 92 2 17.28 11.29 2.78 45.80
INTRACARDIAC THROMBUS 88 2 16.31 10.80 2.66 43.84
CEREBELLAR STROKE 74 1 14.87 18.16 2.52 130.59
LYMPHOPENIA 73 1 14.63 17.91 2.49 128.85
CEREBRAL MASS EFFECT 70 1 13.90 17.17 2.39 123.63
RIGHT VENTRICULAR DILATATION 67 1 13.17 16.44 2.28 118.40
CARDIAC ASSISTANCE DEVICE USER 72 2 12.47 8.83 2.17 35.99
DYSPNOEA AT REST 70 2 12.00 8.59 2.11 35.01
PERCUTANEOUS CORONARY INTERVENTION 70 2 12.00 8.59 2.11 35.01
PERIPHERAL ARTERY THROMBOSIS 68 2 11.52 8.34 2.04 34.03
MYOCARDIAL STRAIN 59 1 11.23 14.48 2.01 104.47
PORTAL VEIN THROMBOSIS 66 2 11.05 8.10 1.98 33.05
PULMONARY PAIN 62 2 10.10 7.61 1.86 31.09
HAEMOFILTRATION 52 1 9.54 12.76 1.76 92.28
IMPLANTABLE CARDIAC MONITOR INSERTION 52 1 9.54 12.76 1.76 92.28
CRITICAL ILLNESS 57 2 8.93 6.99 1.71 28.64
MESENTERIC VEIN THROMBOSIS 49 1 8.82 12.02 1.66 87.06
NIH STROKE SCALE 47 1 8.34 11.53 1.59 83.57
NEUROLOGIC NEGLECT SYNDROME 46 1 8.10 11.29 1.56 81.83
NIH STROKE SCALE ABNORMAL 45 1 7.86 11.04 1.52 80.09
THROMBOEMBOLECTOMY 45 1 7.86 11.04 1.52 80.09
CORONARY ARTERY DISSECTION 44 1 7.63 10.80 1.49 78.35
JUGULAR VEIN THROMBOSIS 44 1 7.63 10.80 1.49 78.35
INTERNAL HAEMORRHAGE 48 2 6.84 5.89 1.43 24.22
COR PULMONALE ACUTE 42 1 7.15 10.30 1.42 74.87
LEFT VENTRICULAR DILATATION 40 1 6.67 9.81 1.35 71.38
NIH STROKE SCALE SCORE INCREASED 40 1 6.67 9.81 1.35 71.38
AORTIC DISSECTION 43 2 5.70 5.28 1.28 21.77
LUNG ASSIST DEVICE THERAPY 42 2 5.47 5.15 1.25 21.28
MYOCARDIAL FIBROSIS 42 2 5.47 5.15 1.25 21.28
CORONARY ANGIOPLASTY 37 1 5.96 9.08 1.25 66.16
CARDIAC FAILURE CHRONIC 40 2 5.02 4.91 1.19 20.30
PERIPHERAL ARTERY OCCLUSION 35 1 5.49 8.59 1.18 62.68
ARTERIAL CATHETERISATION 38 2 4.58 4.66 1.12 19.32
HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 33 1 5.03 8.10 1.11 59.19
HEPATIC MASS 33 1 5.03 8.10 1.11 59.19
BREATH SOUNDS ABSENT 37 2 4.36 4.54 1.09 18.83
SUBDURAL HAEMORRHAGE 37 2 4.36 4.54 1.09 18.83
ACUTE CARDIAC EVENT 32 1 4.79 7.85 1.07 57.45
MITRAL VALVE CALCIFICATION 29 1 4.10 7.12 0.97 52.23
IMPAIRED QUALITY OF LIFE 43 4 3.05 2.64 0.95 7.35
PAIN ASSESSMENT 9 1 0.14 2.21 0.28 17.43